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ABSTRACT 
 
Introduction: Severe and diverse deficits in cognitive, behavioural, social, emotional and 
physical domains are well documented in individuals following a traumatic brain injury 
(TBI). Many treatment options have been investigated, with varying quality of evidence (e.g. 
cognitive rehabilitation, talking therapies, pharmaceutical interventions). Neurofeedback 
involves the real-time recording of brain patterns that are presented back to the individual. 
The individual then uses self-regulation to normalise or optimise neuronal activity and 
modify specific behaviours or cognitive function. This systematic review aims to evaluate 
the effectiveness of neurofeedback in improving behaviour or cognition in the TBI 
population, and assess the methodological quality of the research in this area. 
 
Methods. Five databases were electronically searched. Three studies met the 
inclusion/exclusion criteria. The Clinical Trials Assessment Measure (CTAM) was used to 
assess methodological quality. A meta-analysis could not be carried out due to study 
heterogeneity. 
 
Results. Small to large effect sizes were found across measures of post-brain injury 
symptoms, mood and fatigue, compared to a control group. Medium to large effect sizes 
were found for measures of quality of life, compared to control group. However, studies are 
limited by poor methodological quality. 
 
Discussion. There is promising evidence for the potential effectiveness of neurofeedback in 
the management of post-brain injury symptoms. However, findings are limited by a lack of 
high-quality evidence. Ongoing studies may offer more robust evidence for the role of 
neurofeedback in the TBI population. 
 
Keywords: Traumatic Brain Injury, Neurofeedback, Systematic Review, Rehabilitation 
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INTRODUCTION 
 
Traumatic Brain Injury (TBI) “is involved in nearly half of all trauma deaths” and has “great 
economic costs for individuals, families and society” (WHO, 2006: p164). A recent meta-
analysis of TBI incidence reported a rate of 262 per 100,000 per year (Peeters, 2015). Severe 
and diverse deficits in cognitive (Millis et al, 2001), behavioural (Benedictus, Spikman & 
van der Naalt 2010), social (Colantonia et al, 2004), emotional (Pachalska et al, 2011) and 
physical (Langlois, Rutland-Brown & Wald, 2006) domains have been well documented 
following TBI. 
 
Clinical Guidelines for TBI 
 
Clinical guidelines offer recommendations for improving the cognitive and psychosocial 
consequences following brain injury in adults (Bayley et al, 2014; Rees et al, 2017: Scholten, 
Vasterling & Grimes, 2017; SIGN, 2013). This may include cognitive rehabilitation (e.g. 
compensatory strategies, attention retraining; Cicerone et al, 2011) for memory and thinking 
difficulties and individual or group therapy (e.g. Cognitive Behavioural Therapy and 
Mindfulness-Based Stress Reduction) for emotional difficulties such as anxiety, anger and 
post-traumatic stress symptoms (Rees et al, 2017; Scholten, Vasterling & Grimes, 2017; Soo 
& Tate, 2007; The Matrix, 2015). Recommendations also include contingency management, 
positive behaviour interventions, comprehensive neurobehavioural rehabilitation (Ylvisaker 
et al, 2007), and pharmaceutical interventions (Fleminger, Greenwood and Oliver, 2006) for 
challenging or aggressive behaviour. However, clinical guidelines highlight the lack of high 
quality meta-analyses, systematic reviews and randomised-controlled trials (RCTs) in order 
to provide conclusive results of the effectiveness of cognitive, emotional or behavioural 
interventions in the TBI population (SIGN, 2013). 
 
Research emphasises the use of holistic neuropsychological rehabilitation, which 
incorporates a combination of strategies to improve cognitive, emotional and behavioural 
difficulties (Cicerone et al, 2011; SIGN, 2013). Research has also explored the use of 
biofeedback interventions in the TBI population.  For example, research has explored using 
heart rate variability (e.g. Kim et al, 2013) and neurofeedback (Thornton & Carmody, 2013). 
The use of neurofeedback has also been considered a promising alternative for rehabilitation 
in other areas (e.g. stroke; Renton, Tibbles & Topolovec-Vranic, 2017). 
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What is Neurofeedback? 
 
Neurofeedback is a form of biofeedback. Biofeedback has been used for many decades, most 
commonly to improve symptoms of anxiety using techniques (e.g. relaxation) to alter 
associated physiological measures such as heart rate and galvanic skin response (see 
Schoenberg and David (2014) for review). More recently, the possibility of neurofeedback 
has emerged, which involves the real-time recording of brain patterns, which are then 
presented to the individual via a visual, auditory, touch or electrical stimulation 
representation. The goal is to use self-regulation to normalise or optimise the neuronal 
activity underlying symptoms e.g. cognitive impairment (Yucha & Montgomery, 2008). 
Methods used to measure brain activity include electrophysiological 
(magnetoencephalography (MEG), invasive electrocorticography (ECoG), 
electroencephalography (EEG)), and haemodynamic imaging (functional near-infrared 
spectroscopy (fNIRS), functional magnetic resonance imaging (fMRI)) approaches (Sitaram 
et al, 2016).  
 
For example, EEG neurofeedback involves electrodes placed on the scalp to record brain 
patterns, which are fed back to the individual via computerised software. The individual is 
then trained to alter the brainwave pattern (e.g. speed or size of waves) to increase or 
decrease the brain activity to a pre-specified parameter to improve task performance 
(Enriquez-Geppert, Huster & Herrmann, 2017; Hammond, 2011a). Various neurofeedback 
systems and protocols can be utilised, which may include a normative reference group or 
other pre-determined parameters, and focus on alpha, beta or theta brain wave activity 
(Thornton & Carmody, 2009).  
 
Research into the brain mechanisms underpinning explicit self-regulation is ongoing, with 
several theories proposed, including operant conditioning, motor learning, awareness theory, 
and dual process theory, amongst others (Sitaram et al, 2016). 
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Neurofeedback and TBI 
 
Several studies have explored the use of neurofeedback to improve cognitive function, mood, 
quality of life, pain, and brain activity in the brain injury population (e.g. Keller, 2001; Reddy 
et al, 2013; Surmeli et al, 2017). A non-systematic review of neurofeedback in the TBI 
population identified studies of small sample sizes that found improvements in measures of 
cognition, symptom control (e.g. seizures) and self-reported symptoms such as mood and 
sleep (e.g. May et al, 2013). However, conclusions are limited by the number of databases 
searched (Google Scholartm only) and search terms used (“neurofeedback” and “TBI”; May 
et al, 2013: p.291). Further, there have been several relevant studies published since this 
review (e.g. Rostami et al, 2017; Thornton and Carmody, 2013).A recent systematic review 
of neurofeedback following stroke (Renton, Tibbles & Topolovec-Vranic, 2017) also found 
positive findings from the eight included studies, however studies werealso limited by small 
sample sizes. More promising evidence has been found for improving ADHD symptoms in 
children and adolescents, with a meta-analysis of 10 studies finding a large effect size for 
changes in measures of hyperactivity/impulsivity and medium effect size for changes in 
measures of inattention (N = 256; Van Doren et al, 2018). There is currently no known high 
quality systematic review that evaluates the current evidence of the effectiveness of 
neurofeedback in the TBI population. 
 
Aims 
 
This systematic review aimed to assess whether neurofeedback interventions are effective in 
the management of long-term sequelae of TBI, compared to a control group. 
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METHODS  
 
Search Procedures 
 
The following databases were searched on 2nd September 2017: Cochrane Central Register 
for Controlled Trials (CENTRAL; latest issues); EMBASE (1947 to week of search); 
MEDLINE (1947 to week of search); PsychINFO (1597 to date of search); 
ClinicalTrials.gov (clinicaltrials.gov/). See Appendix 1.2 for search strategies.Included 
studies were hand searched for further articles. The British Library grey literature for 
Medical Sciences database was also searched to identify unpublished dissertations and theses 
(http://ethos.bl.uk). 
 
Inclusion Criteria 
• Types of Studies: Due to the estimated small number of high quality randomised 
controlled trials (RCTs), any study that included an appropriate control group was 
eligible for inclusion.  
• Types of Participants: Studies with adults (≥16 years old) with a TBI (brain damage 
occurring through external trauma after the age of 16 years). 
• Types of Interventions: Any type of neurofeedback intervention (e.g. EEG) where the 
protocol involves conscious (or voluntary) modulation of brain activity, and where the 
primary aim is the management of symptomatic consequences of TBI. 
• Types of Control Groups: Any control condition (e.g. treatment as usual, wait list control 
group, psychoeducation group) where outcome measures have been compared between 
neurofeedback and control groups. 
• Types of Outcome Measures: Any outcome measure that assesses a brain injury-
associated symptom of interest was included (e.g. cognition, emotion, behaviour).  
 
Exclusion Criteria 
• Single case studies 
• Conference abstracts 
• Book chapters 
• Review studies or meta-analyses 
• Commentaries or opinion articles 
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Study Selection and Data Extraction 
 
Titles and abstracts were screened by the lead researcher, discarding those that did not meet 
the inclusion criteria. A second researcher independently screened a proportion (10%) of the 
titles and abstracts to improve the validity of the search. Any disagreements between selected 
studies were resolved via discussion. Eligible studies were then identified via full-text 
retrieval. Where eligibility was unclear, the study was discussed with a senior expert.  Study 
authors were contacted for additional information where necessary. 
 
Each selected study was examined and the following data extracted: participant 
characteristics (e.g. gender, age, traumatic brain injury severity), recruitment information 
(e.g. adherence and attrition), neurofeedback intervention details, method, time-points of 
outcome measure assessments, details of the results (continuous and dichotomous outcome 
data, statistical findings). 
 
Quality Rating 
 
There are several available tools for assessing study quality and risk of bias such as The 
Cochrane Collaboration’s risk of bias tool (Higgens et al, 2011), the Clinical Trials 
Assessment Measure (CTAM; Tarrier & Wykes, 2004), the Risk of Bias in Non-Randomised 
Studies – of Interventions (ROBINS-I; Sterne et al, 2016) and the GRADE guidelines 
(Guyatt et al, 2011). The CTAM was chosen to assess the methodological rigour of each 
study due to the inclusion of items relating to a control group that controls for non-specific 
effects, and an analysis appropriate to the design of the study, which were felt to be critical 
for the design of a high-quality neurofeedback study (see Appendix 1.3). The CTAM was 
developed using the CONSORT checklist of information when reporting an RCT (Schulz, 
Altman & Moher, 2009) to assess the quality of non-pharmacological trials in mental health. 
It contains 15 items in the six domains of sample, allocation to treatment, outcome 
assessment, control groups, analysis, and description/quality of treatments. There is a 
maximum score of 100 points. The CTAM is reported to have excellent concurrent validity, 
good inter-rater agreement, and adequate internal consistency (Wykes et al, 2008). Adequate 
quality was defined as a CTAM score of 65 or above, as suggested by Wykes et al (2008) to 
ensure no domain was of poor quality. Two researchers independently assessed the 
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methodological quality of each study to improve the reliability of assessment. Any 
disagreements were resolved via discussion. 
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RESULTS  
 
Study Selection 
 
Results of the search procedure are illustrated in Figure 1. A search of MEDLINE, 
PsychINFO, EMBASE and Cochrane Central Register for Controlled Trials yielded 2517 
results. After removing duplicates and screening by title and abstract, 11 articles remained 
to be reviewed in full. There were no disagreements between researchers during the 
screening process. Of the remaining articles, eight studies did not meet the 
inclusion/exclusion criteria and were removed; reasons for exclusion can be found in 
Appendix 1.4. The full texts of the remaining three articles met the inclusion criteria for 
quantitative synthesis. Hand-searched reference lists of the included articlesyielded no 
further studies. A search of clinicaltrials.gov identified five relevant ongoing trials (Evans, 
2017; Elbogen, 2018; Glen, 2017; Huang, 2017; Van Boven, 2014). A search of the British 
Library grey literature identified no further relevant results. A total of three studies are 
reviewed; five ongoing studies are also discussed. Due to the small number of studies 
identified, excluded studies that offer additional findings are briefly summarised. 
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Study Characteristics 
 
Table 1 provides details of the characteristics of the three included studies. All three studies 
investigated the use of EEG neurofeedback (Reddy et al, 2013; Rostami et al, 2017; Tinius 
& Tinius, 2001). Outcome measures included cognition (Reddy et al, 2013; Rostami et al, 
2017; Tinius & Tinius, 2001), quality of life (Reddy et al, 2013) and overall post brain injury 
symptom severity e.g. sleep, fatigue, visual difficulties, headache, communication (Reddy 
et al, 2013). No study compared changes in brain wave activity before and after 
neurofeedback. Two types of control group were used including wait-list control (Reddy et 
al, 2013; Rostami et al, 2017), or treatment as usual (Tinius & Tinius, 2001). Tinius and 
Tinius (2001) compared findings from a TBI group with a healthy control group, which did 
not receive the intervention, and an ADHD group, which did receive the intervention. All 
studies gathered pre- and immediate post-intervention data but no study gathered long-term 
follow-up data. 
 
Methodological Quality Rating 
 
There was an average of 82% inter-rater reliability for quality ratings, with some 
disagreement regarding appropriateness of analyses and suitability of the control group. It 
was agreed that analyses were considered appropriate when neurofeedback training was 
found to produce expected changes in brain activity, rather than changes in cognitive or self-
reported outcome measures alone. A suitable control group which was considered to control 
for non-specific effects was agreed to include a sham neurofeedback or other active control 
group (e.g. EMG biofeedback). A wait-list group was not considered to be a suitable control 
group.  
 
Final methodological quality ratings ranged from 21-32. Therefore no studies were 
considered to meet adequate methodological quality, as determined by Wykes et al’s (2008) 
cut-off of 65. 
 
Sample 
 
All three studies used a convenience sample of clinic attenders. Tinius and Tinius (2001) 
also likely included volunteers for a healthy control group, however this was unclear. Reddy 
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et al (2013) included a sample size greater than 27 participants in each group, and therefore 
was the only study to meet the sample size requirement for this CTAM item (Tarrier & 
Wykes, 2004). No study provided a justification for their sample size, or completed a post-
hoc power calculation. 
 
Allocation 
 
Two of the three studies reported using randomisation to allocate participants to treatment 
or control groups (Reddy et al, 2013; Rostami et al, 2017). However no details were provided 
regarding the process of randomisation or whether randomisation was carried out 
independently from the research team. The third study used a control group consisting of 
healthy participants and a different clinical population and therefore randomisation was not 
possible (Tinius & Tinius, 2001). 
 
Outcome Assessment 
 
None of the studies provided details regarding independent assessment of the outcome 
measures. All three studies used standardised measures to assess symptoms. No study 
indicated how of whether outcome assessments were carried out blind to the treatment group 
allocation, or whether blinding was verified. 
 
Control groups 
 
Two studies used a wait-list control group (Reddy et al, 2013; Rostami et al, 2017).The third 
study used a healthy control group that received no intervention (Tinius and Tinius, 2001). 
No study was considered to have adequately controlled for the non-specific effects of 
neurofeedback. 
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Table 1. Summary of Study Characteristics and Quality Rating for Included Studies 
Study Design Intervention 
Group 
Control Group Intervention Outcome 
Measures 
Primary 
Findings 
CTAM 
rating  
Reddy et 
al 2013 
RCT 
(pre-post 
measures) 
N = 30 (3 
female) 
Mage= 28.27 yrs 
(±7.66) 
Mild-severe 
TBI 
N = 30 (3 female)  
Mage= 30.80 yrs 
(±8.38) 
Mild-severe TBI 
 
 
Intervention: 20 x 40min 
sessions over 4-5 weeks EEG 
NFT to improve alpha/theta 
activity  
Wait-list Control: TAU followed 
by intervention 
Post concussion 
symptoms 
RHIFQ, RPQ, 
VAS 
Cognition 
NIMHN 
Quality of Life 
QOL 
Significant 
improvements 
across all 
outcome 
measures post-
intervention, 
compared with 
control group. 
34 
Rostami 
et al 
2017 
RCT 
(pre-post 
measures) 
N = 8) (all male 
Mage= 26.75 yrs 
(±15.16) 
Mild-mod TBI 
N = 5 (all male) 
Mage= 27.60 yrs 
(±8.17) 
Mild-mod TBI 
Intervention: 20 sessions NFT 
across weeks 1-4 (5 per week) to 
improve beta and alpha activity 
Wait-list Control: TAU followed 
by intervention 
Cognition 
WMS-IV, DUAF 
No significant 
improvements 
found between 
intervention and 
control groups. 
24 
Tinius & 
Tinius 
2001 
Non-RCT 
(pre-post 
measures) 
N = 16 (11 
females) 
Mage (SD) = 
29.0 (11.4) 
Mild TBI 
Non-TBI -  
N = 15 (7 females) 
Mage (SD) = 25,1 
(6.8) 
ADHD -  
N = 13 (9 females) 
Mage (SD) = 37.4 
(10.2) 
Intervention: 30-45mins 
computerised EEG 
neurofeedback via coherence 
training with simultaneous 
cognitive retraining  
Average number sessions (SD): 
TBI = 21.2 (4.7) 
ADHD = 18.5 (4.3) 
Non-TBI group received no 
intervention 
Cognition 
FSAQ, IVA CPT, 
NIS, WAIS-R, 
WCST 
Post-Concussion 
Symptoms 
NIS 
Significant 
Group by 
Treatment 
Interaction 
across 
measures. 
21 
Abbreviations: DUAF = unreferenced attention test; IVA CPT  = Intermediate Visual and Auditory Continuous Performance Test; NIMHN = National 
Institute of Mean Health and Neurosciences; NIS  = Neuropsychological Impairment Scales; QOL = Quality of Life Scale; RHIFQ = Rivermead Head 
Injury Follow-up Questionnaire; RPQ = Rivermead Post-Concussion Symptoms Questionnaire; TAU = Treatment as Usual; VAS = Visual Analog 
Scale; WAIS-R = Wechsler Adult Intelligence Scale – Revised; WCST  = Wisconsin Card Sorting Test 
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Analysis 
 
All three studies provided details of statistical analyses. No study analysed whether the 
neurofeedback intervention produced expected changes in brain activity, therefore no 
conclusions could be made as to whether the neurofeedback was effective in modifying 
targeted brain activity. Therefore, no study was considered to use statistical analyses 
appropriate to the design of the study. All three studies completed between-group analyses 
pre- and/or post-intervention relating to the primary outcome measure(s).  
 
Regarding attrition, Reddy et al (2013) stated 70% of participants dropped out prior to 
randomisation however all participants randomised were subsequently included in the 
analyses. Rostami et al (2017) indicated a greater than 15% attrition rate but no details were 
provided regarding how the data were handled. There was no participant drop-out in the 
third study (Tinius & Tinius, 2001). 
 
Description of Treatment 
 
Two of the three studies provided an adequate description of the treatment (Rostami et al, 
2007; Tinius & Tinius, 2001). All studies referred to a protocol or specific software that was 
being used to complete the intervention. No studies provided details regarding adherence to 
the protocol. 
 
Results of individual Studies 
 
A full summary of the findings of the included studies is provided in Appendix 1.5, including 
group means, standard deviations, and effect sizes. Where possible, effect sizes not included 
in the studies were calculated. One study used non-parametric statistical analyses as some 
data were not normally distributed, therefore effect sizes should be interpreted with caution 
(Reddy et al, 2013). The authors of the same study were contacted to obtain further 
information regarding between-group comparisons. The information obtained highlighted a 
discrepancy between the individual pre- and post-score means and the group mean 
differences, which authors clarified as an error in the published pre- and post-score means. 
The results described here are the updated values obtained from the authors. The authors 
stated the updated scores do not impact the overall findings of the study. 
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There was significant heterogeneity between included studies regarding research design, 
participant characteristics, intervention, outcome measures, statistical analyses and there was 
overall poor study quality. Therefore a meta-analysis could not be carried out. A descriptive 
account and synthesis of the included studies was completed. No imputation was carried out 
for missing data. 
 
Cognition 
Reddy et al (2013) found a statistically significant improvement in the intervention group 
for all measures of cognition (p < 0.05); a statistically significant improvement was found 
in four cognitive measures of the wait-list group (p < 0.05). Small to large effect sizes were 
found for both between-group post-intervention scores (d = 0.14-1.08) and for the mean 
difference between groups (d = 0.01-1.62). 
 
Rostami et al (2017) did not find a significant improvement in cognition in the intervention 
group, or a significant difference between treatment and control groups. There were small 
to large effect sizes across cognitive tasks for both post-intervention scores (d = 0.13-1.27) 
and for mean differences (d = 0.09-1.44) between groups.  
 
Tinius and Tinius (2001) found a significant Group by Treatment Interaction across sub-
scores of the Intermediate Visual and Auditory Continuous Performance Test (IVA CPT) 
outcome measures (p< 0.05). Post-hoc tests found mild TBI and ADHD groups to score 
significantly less compared to the control group at pre-intervention, which was no longer 
found at post-intervention. Small to large effect sizes were found for post-intervention 
comparisons between mild TBI and control group scores (d = 0.01-0.91). A significant 
Group by Treatment Interaction was also found across sub-scores of the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R; Wechsler, 1981); effect sizes could not be calculated 
as means and standard deviations were not provided.  
 
Quality of Life 
Reddy et al (2013) found a statistically significant improvement in quality of life in the 
intervention group (p <0.001); a statistically significant improvement was not found in the 
wait-list group. Medium to large effect sizes were found for both post-intervention scores (d 
= 0.70-1.18) and the mean difference (d = 0.75-1.57) between groups. 
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Post-Concussion Symptoms 
Reddy et al (2013) found a statistically significant improvement in the intervention group 
for two post-concussion symptoms questionnaires (p <0.001); a statistically significant 
improvement was also found in the wait-list group (p <0.05). Large effect sizes were found 
both for post-intervention scores (d = 1.00-2.10) and the mean difference (d = 1.47-3.25) 
between groups. 
 
Tinius and Tinius (2001) found a Group by Treatment Interaction for self-reported 
symptoms. Post-hoc tests found a significantly higher score in the mild TBI group pre-
intervention, compared to the control group, which was no longer found post-treatment for 
several measures. Small to large effect sizes were found for post-intervention comparisons 
between mild TBI and control group scores (d = 0.46-1.39) 
 
Brain Activity 
No study reported brain activity recordings, or compared brain wave recordings pre- vs post- 
intervention, or between intervention and control group. Reddy et al (2013) stated “there 
was not statistically significant improvement in the EEG post neurofeedback” (Reddy et al, 
2013: p. 221) however no details of the data or analyses were reported. 
 
Excluded Studies 
 
It is worth noting that several excluded studies have included analyses of brain activity 
following neurofeedback. For example, Keller (2001) explored neurofeedback to improve 
attention, and found increased beta wave brain activity for participants in the neurofeedback 
group. However between-group comparisons were not completed. Other single case (Nash, 
2005) and cohort (Rostami et al, 2011; as cited by May et al, 2013) studies have also found 
normalisation or improvements in brain wave activity following neurofeedback sessions (see 
May et al, 2013 for review). 
 
Ongoing Studies 
 
Table 2 provides details of the characteristics of the five relevant ongoing studies. All five 
studies propose an RCT design including a neurofeedback group and at least one control 
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group. Two studies estimate a small sample size of 14 (Evans, 2017) or 20 (Glenn, 2017) 
and three estimate a large sample size of over 100 (Elbogen, 2018; Huang, 2017; Van Boven, 
2014). All four studies include measures of cognition and other self-reported measures (e.g. 
pain, mood), as well as measures of brain activity. 
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Table 2. Summary Of Study Characteristics For Ongoing Studies 
Study ID, Status Design Participant 
Characteristics 
Intervention Outcome Measures 
Evans 2017 
NCT03324178, 
Recruiting 
Pilot 
RCT 
14 participants 
with a non-
progressive brain 
injury and 
impaired 
sustained 
attention  
Intervention: 16 x 30min sessions of 
neurofeedback over four weeks 
Control: 16 x 30min sessions of video game 
playing over four weeks 
Both groups will complete 16 x 30min 
sessions involving 7 x 3min blocks with 3min 
rest 
Cognition: MAAS, CTET, TEA 
Elbogen 2018 
NCT02237885, 
Not Yet 
Recruiting 
RCT 300 veterans with 
a TBI and self-
reported 
moderate-severe 
musculo-skeletal 
and/or 
neuropathic pain 
Arm I: Mobile App mindfulness 
Arm II: Mobile App neurofeedback 
Arm III: Mobile App Relaxation 
All conditions will engage in the Mobile App 
for a minimum of 10minutes a day, 4 days 
per week, for 12 weeks. 
Pain: DVPRS 
EEG changes: changes in alpha power 
Glenn 
2017 
NCT02615535, 
Active, not 
recruiting 
 
RCT 20 participants 
with a TBI 
randomly 
allocated via 
parallel 
assignment 
Intervention: EEG neurofeedback-assisted 
Meditation 
Control: non-EEG feedback-assisted 
meditation 
Both groups will completed approximately 10 
minutes of daily meditation for 6-8 weeks. 
Neurobehavioural Symptoms: NIS 
Cognition: WAIS-IV Subtests (Digit Span, Digit 
Symbol Coding, Trail Making Test) 
Mood: BAI, BDI-II 
Mindfulness: CAMS-R 
EEG: Percentage of EEG activity associated with 
alpha, beta, and theta rhythms 
Huang 2017  
NCT03244475, 
Recruiting 
Double
-blind 
RCT 
175 participants 
that are veterans 
with a mild TBI 
Intervention: EEG across 14 visits with a one 
week follow-up 
Placebo Comparator: Sham EEG 
Control: no intervention 
Post-Battle Experience: DRRI-2 
Lifetime history of TBI: OSU TBI-ID 
Sleep: PSQI 
Pain: MGPQ 
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Both Intervention and Placebo Comparator 
groups will have 14 active visits, with a 
follow up visit at one week and one month. 
Psychiatric Symptoms: MINI-7 
PTSD: CAPS-5 
Post-Concussion: PCL-5 
Alcohol/Substance Use: ASSIST, AUDIT 
Cognition: CVLT-II, WAIS-IV, DKEFS, CPT-II, 
BIS, FrSbe, WTAR, ToMM, CogState Ltd 
EEG: number of abnormal MEG slow-waves 
MRI: MRI T1-weighted 3D-IRSPGR pulse 
sequence, susceptibility weighted MRI 
Van Boven 
2014 
NCT01908647, 
Unknown 
Status 
RCT 150 participants: 
18-45years old 
with mild TBI 
and cognitive 
dysfunction 
randomly 
allocated via 
parallel 
assignment 
 
Arm I: fMRI with neurofeedback and 
computer based attention training 
Arm II: fMRI with neurofeedback and control 
cognitive training condition (computer-based 
games) 
Arm III: fMRI without neurofeedback and 
computer based attention training. 
Arm IV: fMRI without neurofeedback and 
control cognitive training condition 
All conditions to be completed over 8 weeks 
Cognition: Neuropsychological assessment 
Functioning: Undisclosed self-reported measure, 
TIADL, MPAI-4 
Working/School Status: Employment/schooling 
status, number of hours in work/school/volunteering 
per week 
Exercise: Undisclosed exercise-based assessments 
Abbreviations: ASSIST = Alcohol, Smoking and Substance Involvement Screening Test; AUDIT = Alcohol Use Disorders Identification Test; BAI = 
Beck Anxiety Inventory; BDI-II = Beck Depression Inventory-II; BIS = Barratt Impulsivity Scale; CAMS-R = Cognitive and Affective Mindfulness 
Scale-Revised; CAPS-5 = Clinician-Administered PTSD Scale-5 for DSM-5; CPT-II = Connors Continuous Performance Task-II; CTET = Continuous 
Temporal Expectancy Test; CVLT-II =California Verbal Learning Test-Second Edition; DKEFS = Delis Kaplan Executive Function System; DRRI-2 
=Deployed Risk and Resilience Inventory 2; DVPRS = Defense and Veterans Pain Rating Scale; FrSbe = Frontal Systems Behaviour Scale; MAAS = 
Mindful Attention Awareness Scale; MEG = Magnetoencephalography; MGPQ = McGill Pain Questionnaire; MINI-7 =Mini-International 
Neuropsychiatric Interview;MPAI-4 = Mayo-Portland Adaptability Inventory; NIS= Neurobehavioral Symptom Inventory; OSU TBI-ID= Ohio State 
University Traumatic Brain Injury Identification Method; PCL-5 = Post-concussion checklist-5; PSQI = Pittsburgh Sleep Quality Index; TEA = Test of 
Everyday Attention; TIADL = Timed Instrumental Activities of Daily Living; ToMM = Test of Memory Malingering; WAIS-IV =Wechsler Adult 
Intelligence Scale-Forth Edition; WTAR = Wechsler Test of Adult Reading 
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DISCUSSION 
 
Findings 
 
This review aimed to evaluate the current evidence investigating the effectiveness of 
neurofeedback interventions for the management of TBI symptoms. Two randomised 
controlled trials and one non-randomised controlled clinical trial were included in the review. 
Two studies found significant improvements in cognition, compared to control group. One 
study did not find cognition to improve with neurofeedback. One study found improvements 
in quality of life, and two studies found improvements in post-concussion symptoms, 
compared to control group. However, conclusions are limited by study heterogeneity.  
 
All studies were of a low quality rating. Of particular significance was a failure to compare 
brain activity before and after neurofeedback. Therefore findings could not be summarised 
with regard to the effectiveness of neurofeedback protocols in altering brain wave patterns. 
Research investigating the relationship between physiological markers (e.g. heart rate, 
galvanic skin response) and psychological state have been extensively explored (e.g. 
Gorman & Sloan, 2000). Therefore biofeedback interventions targeting these physiological 
markers offer an understood relationship to psychological improvement (Schoenberg & 
David, 2014). However, there are ongoing challenges in understanding the neural 
mechanisms that underpin self-regulation of brain activity during neurofeedback, and 
difficulties with not all participants achieving self-regulation (Sitaram et al, 2016). There is 
evidence to suggest a relationship between anxiety and decreased alpha and increased theta 
waves, and therefore neurofeedback protocols often focus on altering these brain waves (e.g. 
Moore, 2000; Ros et al, 2014). However further research is required to identify the process 
in which these brain wave patterns are altered e.g. relaxation, cognitive tasks (Sitaram et al, 
2016). Therefore it is important for studies to include measures of brain activity and to 
analyse whether the chosen neurofeedback protocol and self-regulation approach has been 
effective, to improve the validity of the findings. 
 
The control groups’ chosen were not considered appropriate with regard to controlling for 
non-specific effects of neurofeedback. For example, the use of an active control group, as 
well as including other key aspects of being involved in this type of intervention (e.g. 
exposure to a therapeutic environment, positive expectations, motivation for improvement) 
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have been indicated as important contributions for positive findings (Loo & Makeig, 2012). 
Future studies using an active (e.g. EMG) or sham neurofeedback would offer higher quality 
findings into the effectiveness of neurofeeback interventions.  
 
All three studies also failed to gather long-term follow-up data. Further, ongoing emotional, 
addictions and social circumstances impacting recovery in the TBI population (e.g. Corrigan, 
1995; Ponsford et al, 2000; Ruff, Camenzuli & Mueller, 1996) may influence long-term 
outcomes of neurofeedback interventions. It is also unrealistic to expect wide ranging 
changes to quality of life with such a focused intervention as neurofeedback. Therefore 
future studies that collect long-term follow-up data and include these variables as potential 
confounding factors may offer further evidence as to the effectiveness of neurofeedback in 
improving the outcomes of individuals with a TBI. 
 
Limitations of the Review 
 
Four databases were searched, which included published studies, and the references of 
included studies were hand-searched. One database was searched for identification of 
unpublished dissertations and theses, and one database was searched to identify ongoing 
clinical trials. Nevertheless, the review may have failed to identify all eligible studies, 
particularly those that have not been published. Further, due to the inclusion criteria chosen, 
very few studies were included in the review and, as such, excluded non-controlled studies 
may have offered some useful findings that were not summarised. Study quality findings are 
also restricted by the quality measure selected. An alternative quality rating tool may have 
provided additional findings in areas not evaluated by the CTAM, e.g. bias due to 
confounding (Sterne et al, 2016). Other risk of bias tools also offer the opportunity to explore 
other sources of bias that may be specific to the study of interest (Higgins et al, 2011). 
Nevertheless, due to the nature of the intervention, the inclusion of studies with a control 
group and appropriate between group comparisons was considered paramount for a high 
quality systematic review, and therefore the CTAM was chosen in an attempt to offer the 
best conclusions. 
 
Conclusions 
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Due to the lack of eligible studies, and the included studies being of low-quality, the overall 
applicability of the evidence for clinical practice is limited. Further, as the studies were rated 
as low-quality, any findings should be interpreted with caution. There are guidelines 
available for the use of neurofeedback, developed by the International Society for 
Neurofeedback and Research (ISNR; Hammond et al, 2011b).Whilst there is currently 
insufficient evidence to make any recommendations regarding the clinical use of 
neurofeedback in the TBI population, researchers may wish to use these guidelines when 
developing studies to exploreneurofeedback further. Nevertheless this review highlights the 
need for further research,and current ongoing clinical trials may be able to offer stronger 
evidence, with appropriate power, which explore the effectiveness of neurofeedback in the 
TBI population. 
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PLAIN ENGLISH SUMMARY 
 
Introduction 
People with a brain injury often have difficultly regulating their emotions. These difficulties 
can lead to verbal and/or physical aggression, and subsequently significantly affect their 
ability to live independently. Physiological measures such as heart rate, sweat and 
temperature are sensitive to changes in emotion. These physical recordings can now be 
collected through wearable devices (smartwatches). With the development of computer 
science approaches, it is possible to use information from one set of data to make predictions 
about another. This approach would be useful if it can be applied to physiological recordings 
to predict verbal or physical aggression in the future. 
 
Aims  
This study investigated whether computer scienceapproaches could be used to predict 
physical and verbal aggression before it happens. 
 
Method 
Participants were recruited from a brain injury inpatient rehabilitation unit. They were asked 
to wear a smartwatch and were prompted to wear the smartwatch at all times, apart from in 
the shower, and to charge the smartwatch each day. They were also asked to carry a phone 
on their person, which was used to store the information gathered on the smartwatch. During 
this time, staff recorded physical and verbal aggression.  
 
Results 
Five patients were included in the study. Technical and practical problems made data 
collection difficult. These included WiFi connection problems, forgetting to charge and wear 
the smartwatch or carry the phone, and smartwatches breaking. It was not possible to explore 
the computer science approaches with two participants, as there were too few aggressive 
behaviours observed by staff. Therefore, computer science approaches were used to create 
calculations on available data for three participants. Although the calculations created were 
able to predict some episodes of aggression, there were also many false alarms where 
aggression was incorrectly predicted. Possible reasons included a lack of sufficient observed 
aggressive behaviours for developing the calculations, staff failures to report all aggressive 
behaviours leading to some physical recordings being labelled incorrectly, and changes in 
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physical recordings associated with stress that did not ultimately lead to an aggressive 
behaviour.  
 
Conclusions 
The identification of a potential tool for predicting physical and verbal aggression would 
provide important warning signs to help patients and staff alleviate distress and prevent the 
aggressive behaviour occurring. In the current study, it was not possible to develop a 
calculation that predicted future episodes of aggressive behaviour, without too many false 
alarms for it to be useful in a real-world inpatient environment. Nevertheless, the current 
study provides useful insight into conducting technology research in the brain injury 
population. Recommendations for future research would include a careful choice of 
smartwatch that is durable, with a long battery life and large storage capacity, a reliable 
Internet connection, and prompts for individuals with memory difficulties. It might also be 
useful to use a patient questionnaire to measure times of stress, in order to determine whether 
calculations can also be used to predict increased stress levels, which may not lead to an 
aggressive behaviour.  
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ABSTRACT 
 
Introduction. Emotional dysregulation often occurs in people with an acquired brain injury 
(ABI), and can lead to challenging behaviour including aggression. Emotion regulation is 
associated with the autonomic nervous system and physiological recordings (e.g. heart rate 
variability) can be used as index measures of self-regulation. The development of wearable 
devices allows for real-time continuous physiological recording. Advances in machine 
learning techniques also open avenues for analysing these data, which involves identifying 
patterns to predict behaviours. This study aimed to explore whether physiological and sleep 
recordings could be used to accurately predict challenging behaviour in individuals with an 
ABI. 
 
Methods. Participants were recruited from a brain injury inpatient unit. Participants wore a 
Smartwatch, which collected physiological and sleep data. Staff recorded episodes of verbal 
and physical aggression. Ethical approval was obtained for the study. Data mining 
techniques were used to develop models for predicting aggressive behaviour.  
 
Results. Five participants were included in the study. Technical and practical problems led 
to unanticipated data collection difficulties, including participants failing to wear or charge 
the devices, smartwatches breaking, and poor WiFi connection. Machine learning was used 
to create predictive models both for individual participants, and a combined model. Models 
successfully predicted 9-100% or episodes of aggressive behaviour however there were a 
large number of false alarms impacting the clinical applicability of the models. 
 
Discussion. This study failed to create a model that predicted episodes of aggression without 
a sufficiently low number of false alarms that would suggest it was clinically useful in an 
inpatient setting. Several possible reasons are discussed. Practical recommendations for 
future research include a careful choice of smartwatch,a reliable internet connection, 
consistent aggression reporting, and the inclusion of a self-reported measure of emotional 
dysregulation.  
 
Conclusions. The development of a clinical tool that can accurately predict and warn 
individuals, or staff, of imminent emotional dysregulation opens avenues for its prevention. 
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This study provided useful insight into the initial attempts to explore this using a machine 
learning approach in the ABI population.  
 
Keywords: acquired brain injury, wearable devices, challenging behaviour
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INTRODUCTION 
 
Emotional Dysregulation 
The ability for humans to regulate their emotions involves a complex interplay between 
affective, cognitive, behavioural, and physiological systems, enabling us to interact 
effectively with our environment. When working well, this network of connected systems 
allows individuals to cope with, and respond to, difficult emotions, and to coordinate 
selection of an appropriate goal-directed behaviour whilst inhibiting inappropriate 
behaviours (Thayer et al, 2012). This process involves multiple feed-forward and feedback 
mechanisms occurring in less than a second, including information processing, appraisal of 
threat, biochemical processes (e.g. hormone release), coordination of breathing rate, and 
muscle contraction (Thayer & Lane, 2000). When this network is not working effectively, 
individuals can become stuck in a pattern of inappropriate behaviours that are maladaptive 
to the demands of the environment. This dysregulation has been associated with self-
monitoring and self-awareness difficulties, and can result in mental and physical health 
pathologies, such as generalised anxiety disorder and hypertension (Thayer & Lane, 2000).  
 
Difficulty identifying emotions in the self (alexithymia), empathy and social cognition are 
more prevalent following an acquired brain injury (ABI) than the general population 
(McDonald, 2013; Wood & Williams, 2007). This can lead to emotional dysregulation and 
often presents as behaviours that challenge care providers (Tateno, Jorge & Robinson, 2003). 
Several measures have been developed to record challenging behaviour that have strong 
inter-rater reliability within the neurological population, such as the Overt Behaviour Scale 
(OBS; Kelly et al, 2006), the Over Aggression Scale (Yudofsky et al, 1986), which are often 
reported by an individual in close contact with the person e.g. staff or family member. For 
example, a study of 507 severe ABI patients reported 54% to exhibit challenging behaviour 
as assessed using the OBS; inappropriate social behaviour was most commonly reported 
(33%; Sabaz et al, 2014). A study of 227 moderate to severe traumatic brain injury (TBI) 
patients found 25% to exhibit aggressive behaviour (Baguley, Cooper & Felmingham, 2006). 
These behaviours can lead to difficulties with educational, vocational, and social pursuits, 
and family re-integration (Morton & Wehman, 1995; Ylvisaker, Turkstra & Coehlo, 2005).  
 
Physiological Indicators of Emotional Dysregulation 
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Physiological measures involved in autonomic nervous system (ANS) regulation have been 
associated with emotion regulation (Thayer et al, 2012). Cardiac vagal tone has been 
identified as an indicator of ANS regulation. High cardiac vagal tone has been associated 
with behavioural flexibility and environment adaptability, whereas low cardiac vagal tone is 
associated with reduced ability to assess the environment and organise an appropriate 
response, the latter leading to emotional dysregulation (Thayer & Lane, 2000). Cardiac vagal 
tone is reflected in heart rate variability (HRV), which is a measure of the change (or 
variability) in time between successive heartbeats, measured in milliseconds. A meta-
analysis of functional neuroimaging studies identified a relationship between HRV and the 
amygdala and ventromedial prefrontal cortex, brain areas associated with cognitive, 
emotional and behavioural responses (Thayer et al, 2012). Other indicators of ANS arousal 
and emotion regulation include skin resistance (a measure of sweat; Critchley et al, 2000), 
skin temperature (Gross, 2002) and sleep quality (Mauss, Troy & LeBourgeois, 2013). In 
the ABI population, lower HRV has been associated with poorer social and emotional 
functioning (Francis et al, 2015), antisocial and violent behaviour (Raine, 2002) and 
worsened neurological state (Rapenne et al, 2001). Sleep disturbance also commonly occurs 
following brain injury (e.g. Orff, Ayalon & Drummond, 2009; Parcell et al, 2008) and 
evidence has found poor sleep to be associated with aggression (Kamphuis et al, 2012). For 
example, research has proposed that the prefrontal cortex and amygdala may be dependent 
upon homeostasis of the sleep system, suggesting poor sleep leads to impulsivity and 
emotional reactivity (Gruber and Cassoff, 2014). Evidence also supports the association of 
aggressive behaviour with skin resistance (Raine, 2002).  
 
Physiology and Technology 
Research previously relied on large technical devices, such as functional MRI machines to 
measure brain activity and electroencephalography (EEG) to measure sleep, or awkward 
devices, such as finger electrodes to measure skin conductance and chest straps to measure 
HRV. These devices often meant participants were monitored for short time periods in 
laboratory settings. The emergence of wearable physiological monitoring systems now 
allows individuals to wear devices throughout the day and track their physiology via a 
mobile phone application. A review of 17 wearable fitness trackers found heart rate and step 
count to have an accuracy of 79.8-99.1%, when compared to observer-counted steps and a 
heart rate recording medical device (El-Amrawy & Nounou, 2015). Therefore the evolution 
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of accurate wearable devices broadens research opportunities for measuring emotion 
regulation in real-time (Banee, Ahemed & Loutfi, 2013).  
 
Research investigating wearable devices to measure physiology and infer emotional states, 
is in its infancy. Advances in machine learning offer approaches to help make sense of large 
quantities of sensory information from wearable devices (Banee, Ahmed & Loutfi, 2013). 
Machine learning uses data mining processes, which typically involves data collection, 
preprocessing, defining features, modelling and model testing (e.g. Hand, 2007). This can 
provide valuable information for identifying patterns that can aid diagnosis, prediction and 
anomaly detection (Banee, Ahmed & Loutfi, 2013). For example, specific data mining 
techniques can interpret continuous data (e.g. heart rate) and detect, or predict, 
inconsistencies in patterns to indicate abnormal behaviour (e.g. stress; Sun et al, 2012). 
Previous research using physiological recordings collected from wearable devices has found 
promising findings for identifying poor mental health and for predicting future stress levels 
(Ghandeharioun et al, 2017; Sano et al, 2018; Umematsu et al, 2018). 
 
Research in the ABI population has focused on using physiological measures for 
biofeedback. Biofeedback aims to alter a person’s physiological activity via (in)voluntary 
self-regulation, to improve physical or mental functioning (e.g. Kim et al, 2015). However 
biofeedback interventions often involve prescheduled time-limited sessions. The use of a 
wearable device that continuously monitors physiological recordings, with the ability to 
indicate increased stress levels, could help individuals prevent (potentially) harmful 
emotional dysregulation. There is limited research that has investigated data mining 
techniques for predicting future episodes of emotional dysregulation using physiological 
data. Recent research with two participants has found promising evidence with successful 
predictions of up to 82% of aggressive behaviours up to four hours prior to their occurrence 
(Turner et al, 2017). The current study aimed to provide further evidence for the ability to 
predict future episodes of aggression via data mining approaches in individuals with an ABI, 
using a wearable device. 
 
Aims 
To investigate whether a machine learning model can be developed to predict aggressive 
behaviour prior to it’s occurrence, using data collected from a smartwatch. 
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Hypotheses 
• A machine learning model can be developed to predict aggressive behaviour one 
hour in advance, using physiological data. 
• A machine learning model can be developed to predict aggressive behaviour using 
sleep data the night before it occurs. 
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METHOD 
 
Ethical Approval 
Ethical approval was sought from the North of Scotland NHS Research Ethics Committee 
and the Disabilities Trust Research Ethics Committee (Appendix 2.1). Approval via the 
Medicines and Healthcare products Regulatory Agency was not required, as the study did 
not involve randomisation, change to standard treatment or aim to claim generalisation of 
findings. NHS Research and Development approval was not required, as the research was 
conducted at a non-NHS site.  
 
Design 
A case series design was used.  
 
Participants 
Participants were recruited from Graham Anderson House (GAH), a specialist assessment 
and rehabilitation hospital for people with complex needs requiring residential support 
following a non-progressive ABI.  
 
Eligibility Criteria 
Participants had sustained a severe brain injury, were aged ≥16 years old, were presenting 
with challenging behaviour during the recruitment period, and were deemed to have capacity 
to consent to participation in research by professionals responsible for their care.  
 
Recruitment 
The recruitment period was between 2nd April and 7th May 2018. Seven identified 
participants met inclusion criteria. After being approached regarding participation by the 
clinical team, a member of the research team approached participants to discuss the details 
of the study. This included information regarding data collected by the devices, device 
maintenance, and data confidentiality. Participants were also provided with an information 
sheet and offered at least 24 hours before obtaining written informed consent (Appendices 
2.2, 2.3). Two participants were withdrawn within two weeks of enrolment as they failed to 
wear the smartwatch. Details of the remaining five participants are provided in Table 1; all 
participants were male and exhibiting both verbal and physical aggression at recruitment. 
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Table 1. Participant Demographics 
 
Participant 
 
1 2 3 4 5 
Age (years) 30-40 40-50 20-30 60-70 30-40 
Brain Injury Type TBI Hypoxia TBI Stroke TBI 
Time since admission >2years  <3months  <6months >1year  >1year 
Number of aggressive episodes reported 
in the eight weeks prior to recruitment 
34  33* 33  24  20  
Note: Demographic ranges used to protect anonymity 
*since admission, TBI = traumatic brain injury 
 
Measures 
 
Aggression - the Overt Aggression Scale - Modified for Neurorehabilitation (OAS-MNR; 
Alderman, Knight & Morgan, 1997) was used to record episodes of aggression. The OAS-
MNR has good inter-rater reliability and validity in an inpatient setting (Alderman, Knight 
& Morgan, 1997). It is routinely incorporated into clinical tools used at GAH (Appendix 
2.5) and forms a key component for reviewing patient progress. 
 
The following measures were obtained from the smartwatch: 
Physiological Data –  
• Average Heart Rate (beats per minute; bpm) 
• Maximum Heart Rate (bpm) 
• Minimum Heart Rate (bpm) 
• Heart Rate Variability (HRV) 
• Step Count 
• Skin Resistance (ohms) 
• Skin Temperature (degrees Celsius) 
Sleep Data –  
• Total Duration (seconds) 
• Time Awake  (seconds) 
• Light sleep (seconds) 
• Number of Wake Ups 
• Sleep Efficiency (percentage of time actually asleep in total sleep period) 
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Materials 
The following equipment and software were utilised: 
1. The Microsoft Band 2 smartwatch was used to record heart rate, heart beat interval, steps, 
skin resistance, skin temperature and sleep.  
2. A Samsung Smartphone was used to gether the smartwatch data via two phone 
applications: 
a. The Microsoft Health application collected and summarised the data in hours 
(heart rate, step count) and nights (sleep). 
b. The TEAMED (Technology Evaluating and Measuring Emotional 
Dysregulation) Patient application collected real-time continuous data from the 
smartwatch to calculate heart rate variability, to collect skin resistance and skin 
temperature data, and identify within-hour changes in physiology (e.g. rising 
heart rate). 
3. The TEAMED Admin computer program was used to monitor data collection and input 
staff-reported aggression reports. 
4. InfluxDB (https://influxdata.com) – this time-series database is run on a secure server 
managed by the University of Stirling and stored data gathered by the TEAMED Patient 
application and aggressive episodes recorded in the TEAMED Admin program.  
5. Microsoft Health Vault – this server is managed by Microsoft and stored data gathered 
by the Microsoft Health application 
 
Procedure 
The data collection period was 2nd April –2nd July 2018. Data was not collected for the first 
three weeks due to technical difficulties requiring re-registering and updating applications, 
leaving a maximum of ten weeks data collection. Following enrolment, participants were 
asked to wear a smartwatch at all times whilst at GAH, including whilst asleep, except when 
showering or charging the watch. Participants were also asked to carry the smartphone on 
their person, or keep the phone within 10metres when asleep (e.g. on bedside table). 
Participants were provided with memory prompts, via a poster in their bedrooms. A member 
of the research team also approached participants on weekdays to offer technical support and 
a further memory prompt, if required. Throughout the study, staff reported aggressive 
behaviours via an adapted OAS-MNR. 
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Data Analysis 
Descriptive Statistics 
Descriptive statistics for physiological and sleep data (average, standard deviation) and type 
and severity of aggression were calculated.  
 
Machine Learning 
The machine learning package Waikato Environment for Knowledge Analysis (WEKA; 
Eibe, Hall & Whitten, 2016) was used. Advice regarding all components of the data analysis 
was sought from Dr Kevin Swingler (Computer Scientist, University of Stirling). One hour 
and the night prior to the aggressive episode were considered a clinically relevant warning 
time in an inpatient setting. 
 
Preprocessing  
Alongside hourly and daily summaries, features were created to account for the continuous 
nature of the data. Hours containing the aggressive episodes were not included in the 
analysis, unless an aggressive episode occurred in the subsequent hour. Data collected from 
the Microsoft Health application were processed to create the following features:  
 
Feature Explanation Variable 
Diff Difference in value 
from hour (physical) 
or day (sleep) before 
Physical – MaxHRDiff, AvHRDiff, 
MinHRDiff, StepCountDiff 
Sleep – DurationDiff, AwakeDiff, 
LightSleepDiff, WakeUpsDiff, SleepEffDiff 
DiffMean Difference in value 
from overall mean of 
value for dataset  
Physical – MaxHRDiffMean 
AvHRDiffMean, MinHRDiffMean 
StepCountDiffMean 
Sleep – DurationDiffMean, AwakeDiffMean,  
LightSleepDiffMean, WakeUpsDiffMean, 
SleepEffDiffMean 
Abbreviations: Diff = Difference, HR = Heart Rate, Av = Average, Min = Minimum, 
SleepEff = Sleep Efficiency 
 
Real-time physiological data collected from the TEAMED Patient application were 
processed by Professor Ken Turner (Computer Scientist, University of Stirling), who created 
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the following features: 
 
Feature  Explanation Variable 
Standard 
Deviation 
(SD) 
Number of standard deviations the 
maximum physiological measure in the 
previous hour is from the mean for the 
hour before that  
HRSD, HRVSD, 
SkinResistanceSD, 
SkinTempSD, StepCountSD 
Peaks Number of peaks in 
physiologicalmeasurefor the previous hour 
HRPeaks, HRVPeaks, 
StepCountPeaks 
SkinTempPeak 
Trough Number of troughs in physiological 
measure for the previous hour 
SkinResistanceTrough, 
 
Trend 
(rising) 
Largest number of rising steps in the 
physiological measure for the previous 
hour 
HRTrend, 
HRVTrendSkinTempTrend, 
StepCountTrend 
Trend 
(falling) 
Largest number of falling steps in the 
physiological measure for the previous 
hour 
SkinResistanceTrend 
Abbreviations: Max = Maximum, HR = Heart Rate, HRV = Heart Rate Variability, 
SkinTemp = Skin Temperature 
There were not enough sleep data collected via the TEAMED Patient application to create 
sleep features. 
 
Preprocessing methods were also used to account for the small number of hours with 
aggressive behaviours, and large number of hours without aggression. Imbalanced datasets 
lead to difficulties implementing data mining techniques to create prediction models, as the 
simplest model is to class all data as ‘normal’ (Chawla et al, 2002). In a real-world setting, 
the cost of ‘misclassifying’ an abnormal event as normal is often much higher than the 
reverse. Two methods were explored to decrease misclassification errors: the Synthetic 
Minority Over-Sampling Technique (SMOTE; Chawla et al, 2002) and Cost Sensitive 
Classification (University of Waikato, 2018a). SMOTE creates new (or ‘synthetic’) data 
points near to collected data points up to a desired percentage. For example, if the majority 
class contained 100 data points and the minority class contained 25 data points, over-
sampling at 400% would create an equal number of data points in each class. Cost-Sensitive 
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Classification increases the “cost” of misclassification and the selected algorithm will 
attempt to produce a model that minimises the number of misclassifications in the chosen 
class (Quin et al, 2010).  
 
Algorithm Selection 
Three algorithms were explored: J48 (Bhargava et al, 2013), Logistic Regression and 
Multilayer Perceptron.  
 
J48 is a decision tree algorithm that makes flowchart-like decisions to classify the dependent 
variable (aggression or no aggression) with the independent variables (physiological and 
sleep data). The first decision is made at the “root node”, which will either lead to a “leaf 
node” (a classification) or an “internal node” (another decision). Below is a simplified 
example for classifying house size: 
   Number of bedrooms (root node)  
   <3    >3 
 Small (6.0)   Number of bathrooms (internal node) 
 (leaf node)   <4  >4 
     Medium (6.0)  Large (3.0) 
     (leaf node)  (leaf node) 
Increasing the minimum number of objects a leaf can contain decreases the number of 
internal nodes. This helps manage the complexity of the tree, and reduces bias to a tree that 
may be overfitting to the training data, and subsequently would poorly predict new testing 
data it is presented with.  
 
Logistic Regression is used to build a model based on the relationship between the dependent 
variable and independent variable(s) to estimate one of two outcomes (Kumar & Sahoo, 
2012). The model is built using coefficients, which measure each independent variables’ 
predictive capability, and odds ratios, which indicate the effect of the independent variable 
on the likelihood the outcome will occur. 
 
Multilayer Perceptron is an artificial “neural network” whereby a network of mathematical 
functions (“hidden layers”) are placed on the independent variables (“inputs”) in order to 
predict the dependent variable (Kumar & Sahoo, 2012). Increasing the number of hidden 
layers increases the model complexity. A simple multilayer perceptron layout is provided 
 48   
below: 
 Input Layer  Hidden Layer  Output Layer 
 
 
Input1 
 
Input2     Output 
 
Input3 
 
 
Modelling 
When building and evaluating a model there is a training phase, a validation phase, and a 
testing phase. The training phase takes a proportion of the data to build the model, and the 
validation phase uses a proportion of the data to validate the predictability of the model. 
These training and validation phases are repeated with all selected algorithms and 
preprocessing methods to develop one final model. The testing phase uses unseen data kept 
separately from the data used in the training and validation phases, which evaluates the final 
predictability of the chosen model.  
 
When carrying out the training and validation phases, a Cross-Validation method can be 
used. Cross-Validation divides a proportion of the data into 10 equal subsets (“folds”), builds 
a model with 9 of the folds, and validates the model on the 10th. This process is repeated 10 
times using different partitions of the same proportion of data. The subsequent model is then 
validated a final time on the entire proportion (University of Waikato, 2012b). This reduces 
overfitting of the model by using different subsets of the data. This method was adopted 
when using Cost-Sensitive Classification. However, this method was not adopted when 
using SMOTE, to ensure the validation phase only contained real data points. Therefore 
when using SMOTE, the data were manually split into a training set (66%) and a validation 
set (33%).  
 
Modelling 
Different models were explored using the three algorithms, and using Cost-Sensitive 
Classification and SMOTE. The following values were obtained to determine the 
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predictability of each model: 
Accurate Predictions Number of correct predictions of aggressive episodes (true 
positives) 
False Alarms Number of incorrect predictions of aggressive episodes 
(false positives) 
Misses Number of aggressive episodes not predicted (false 
negatives) 
Precision Rate of accurate predictions compared with total number of 
predictions  
Recall  Rate of accurate predictions compared with total number of 
aggressive episodes  
 
Precision and Recall values range between 0.00 and 1.00, with 1.00 indicating that all 
predictions were accurate predictions i.e. no false alarms (Precision) or that all aggressive 
episodes were predicted i.e. no misses (Recall).  
 
A final model indicating the best balance between precision and recall values was identified 
for each participant. A model using all available training data across participants was also 
explored, to determine whether a single model could be used to predict aggression. The final 
models were evaluated using the unseen testing data.  
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RESULTS 
 
Attrition 
Three participants withdrew from the study.  
 
Participant 1 sustained an arm injury and chose to withdraw from the study as they did not 
wish to wear the watch on their alternate wrist. This adverse event was not an anticipated 
consequence of participation and was unrelated to the study procedures and device. This led 
to four fewer days of data collection than anticipated. 
 
Participant 3 chose to withdraw from the study due to concerns about losing the phone. This 
led to 24 fewer days of data collection than anticipated. 
 
Participant 5 developed delusional beliefs, associated with social circumstances whilst away 
from the unit and not wearing the devices, and chose to withdraw from the study upon their 
return. This adverse event was not an anticipated consequence of participation was unrelated 
to the study procedures and device. This led to 19 fewer days of data collection than 
anticipated.  
 
Missing Data 
Table 2 provides a summary of data collected for each participant. Reasons for missing data 
included: 
• Participants not charging or wearing the smartwatch or carrying the phone 
• Significant aggression leading to risk associated with prompting participants  
• Staff failing to provide a time on aggression reports 
• Bluetooth reconnection difficulties between the smartwatch and phone  
• WiFi reconnection difficulties causing data to become lost before it could be 
uploaded to the server 
• Smartwatches becoming unusable (e.g. stopped charging, would not switch on, 
buttons not working; reason(s) unknown) 
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Table 2. Summary of Data Collection for Physiological Data, Sleep Data, and Aggression 
Reports 
 
Participant 
1 2 3 4 5 
Data collection period (excluding home passes) 
  
Days (N(hours)) 
N of Nights 
59(1416) 
58 
70(1680) 
69 
40(960) 
22 
70(1680) 
69 
19(456) 
19 
Number of hours physiological data collected (% total) 
  
TEAMED patient 
Microsoft Health 
536(38%) 
1009(71%) 
139(8%) 
803(48%) 
92(10%) 
628(65%) 
270(16%) 
976(58%) 
33(4%) 
369(81%) 
Sleep data collected (excluding home passes) 
 
N of nights(%) 34(59%) 32(46%) 22(100%) 30(43%) 17(89%) 
Aggressive episodes 
    
Total reported 
N reported with 
time/date(%) 
32 
27(84%) 
 
76 
66(87%) 
 
7 
7(100%) 
 
67 
59(88%) 
 
4 
4(100%) 
 
Note: physiological data could not be collected for all aggressive reports 
 
Descriptive Statistics 
 
Figure 1 provides a summary of the types of aggression recorded for each participant. Each 
completed OAS-MNR aggression report (episode) often contained more than one type of 
aggressive behaviour and/or behaviour severity rated from 1 (least severe) to 4 (most severe).  
 
Figure 2 and 3 provide examples of the data gathered for physiological and sleep measures. 
A detailed summary of the means and standard deviations for all variables can be found in 
Appendix 2.5. 
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Aggression Reports 
(1 = Least Severe to 4 = Most Severe) 
 
Figure 1. Summary of Aggressive Behaviour Reports 
 
 
  
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
Verbal
Aggression
Physical
Aggression
Against Objects
Physical
Aggression
Against Self
Physical
Aggression
Against Other
Person
Participant 1 13 11 24 7 1 0 0 0 0 0 0 1 2 1 0 0
Participant 2 5 5 47 2 6 12 0 0 0 1 0 0 22 3 0 0
Participant 3 4 1 3 0 0 0 0 0 0 0 0 0 0 0 0 0
Participant 4 4 10 48 35 6 3 2 0 0 0 0 0 17 5 2 0
Participant 5 0 0 4 3 2 0 1 0 0 0 0 0 0 0 0 0
0
20
40
60
80
100
120
140
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Heart Rate 
 
*Value based on one aggression report 
 
Step Count 
 
*Value based on one aggression report 
 
Skin Resistance and Skin Temperature 
 
*No aggressive episodes captured by the data 
Figure 2. Summary of Heart Rate, Step Count, Skin Resistance and Skin Temperature 
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Average Sleep Values 
 
 
*No aggressive episodes capture by the data 
Figure 3. Summary of Average Sleep Values for Duration Asleep (Duration), Time Awake 
During Sleep Period (Awake), Light Sleep Duration (LightSleep)  
 
Machine Learning 
 
Due to the small number of aggressive episodes for Participant 3 and Participant 5, individual 
models for these participants were not possible with Microsoft Health or TEAMED 
application data. Nevertheless, all participant training and testing data were included in a 
combined model. Due to the lack of consecutive nights of sleep collected by the TEAMED 
application, analysis of this data was not possible.  
 
Details of the characteristics of the final individual and combined models can be found in 
Table 3. Predictability of the final individual and combined models can be found in Tables 
4 and 5, respectively. Appendix 2.6 provides details of alternative models explored. Both 
SMOTE and Cost-Sensitive Classification and all three selected algorithms were chosen 
when developing the models for the Microsoft Health data. Only Cost-Sensitive 
Classification preprocessing could be explored with the TEAMED Application data as there 
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were too few aggressive episodes with associated physiological recordings to explore 
SMOTE. 
 
Physiological Models 
Most individual models developed using Microsoft Health data performed worse in the 
testing phase, identifying 14-33% of reported aggressive episodes compared to 50-71% 
identified in the validation phase. Further, of the model predictions, 94-96% were false 
alarms, compared with actual episodes. Models developed using TEAMED Patient data 
improved in the testing phase for Participants 2 and 4, with 50% and 100% of reported 
aggressive episodes accurately predicted, respectively, compared with 33 and 75% 
predicting during the validation phase.  However, a large proportion of predictions were 
false alarms (90-93%). 
 
The combined model developed using Microsoft Health data performed poorly for 
Participants 1 and 2 in the testing phase, identifying 0% and 29% of aggressive episodes 
respectively. The model improved for Participant 4, identifying 83% of aggressive episodes. 
The combined model developed from the TEAMED Patient data performed poorly across 
participants, identifying 0-50% of aggressive episodes. 
 
Sleep Models 
Individual models developed using Microsoft Health data for Participants 1 and 4 performed 
well in the testing phase, identifying 100% of aggressive episodes, compared with 100% and 
46% identified in the validation phase, respectively. Fifty percent and 60% of predictions 
were false alarms, compared with actual episodes, respectively. The model developed for 
Participant 2 performed worse in the testing phase, identifying 0% of aggressive episodes, 
compared to 25% during the validation phase; therefore 100% of predicted episodes were 
false alarms. Performance of the combined model varied across Participants 1, 2 and 4, 
identifying 0%, 100% and 67% of aggressive episodes respectively in the testing phase; 0%. 
60% and 100% of predictions were false alarms, respectively.  
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Table 3. Summary of Final Models 
  Model Details  
1. Individual Models Participant 1 Participant 2 Participant 4 
Physiological Data    
Microsoft 
Health 
Preprocessing 
Algorithm 
SMOTE (8300%) 
J48 (MinNumObj = 40) 
Cost (45, yes) 
J48 (MinNumObj = 40) 
SMOTE (1200%) 
Logistic Regression 
 Best Predictors MaxHRDiff, AvHRDiff, 
MinHR Diff, StepCount 
MaxHR, StepCount, 
MinHR, MinHRDiff 
AvHRDiffMean, MinHRDiff 
TEAMED 
Patient 
Preprocessing 
Algorithm 
Cost (120, yes) 
Multilayer Perceptron  
(Hidden Layers = 22) 
Cost (65, yes) 
Logistic Regression 
Cost (45, no) 
J48 (MinNumObj = 50) 
 Best Predictors HRSDMax, StepCountPeaks, 
HRTrend 
HRTrend, HRPeaks, 
StepCountTrend 
HRVPeaks 
Sleep Data       
Microsoft 
Health 
Preprocessing 
Algorithm 
SMOTE (400%) 
Logistic Regression 
Cost (1.5, yes) 
J48 (MinNumObj = 3) 
Cost (2, no) 
J48 (MinNumObj = 2) 
 Best Predictors SleepEffDiffMean, WakeUps, 
SleepEff, SleepEffDiff 
SleepEffDiff WakyUpsDiff, WakeUps 
2. Combined Models            Model Details  
Physiological Data Participants 1 - 5 
Microsoft 
Health 
Preprocessing 
Algorithm 
Cost (35, yes) 
Multilayer Perceptron (Hidden Layers = 15) 
 Best Predictors MaxHRDiff, MinHR, StepCountDiff, StepCountDiffMean 
TEAMED 
Patient 
Preprocessing 
Algorithm 
Cost (70, yes) 
Multilayer Perceptron (Hidden Layers = 18) 
 Best Predictors SkinResistanceTrough, SkinResistanceTrend, StepCountPeak, HRVTrend 
Sleep Data     
Microsoft 
Health 
Preprocessing 
Algorithm 
SMOTE (100%) 
Multilayer Perceptron (Hidden Layers = 20) 
 Best Predictors Duration, WakeUpsDiff, DurationDiff, WakeUpsDiffMean 
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Table 4. Summary of Findings of Individual Models 
 Participant 1 Participant 2 Participant 4 
Physiological Data    
Microsoft Health Validation Testing Validation Testing Validation Testing 
Accurate Predictions (N) 3 1 8 3 5 6 
False Alarms (N) 18 67 165 70 56 92 
Misses (N) 2 6  8 5 2 12 
Precision   0.14 0.02 0.05 0.04 0.08 0.06 
Recall  0.60 0.14 0.50 0.38 0.71 0.33 
TEAMED Patient       
Accurate Predictions (N) 2 1 1 1 3 2 
False Alarms (N) 75 14 15 9 57 38 
Misses (N) 2 4 2 1 1 0 
Precision  0.03 0.07 0.06 0.10 0.05 0.05 
Recall   0.50 0.20 0.33 0.50 0.75 1.00 
 
Sleep Data 
     
Microsoft Health       
Accurate Predictions (N) 4 4 3 0 6 3 
False Alarms (N) 1 6 4 0 3 3 
Misses (N) 0 0 9 3 7 0 
Precision  0.80 0.40 0.43 - 0.67 0.50 
Recall  1.00 1.00 0.25 0.00 0.46 1.00 
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Table 5. Summary of Findings of Combined Models 
 
 
Validation 
Phase 
 
Testing Phase 
Physiological 
Microsoft Health 
Participants 1 - 5 Participant 1 Participant 2 Participant 3 Participant 4 Participant 5 
Accurate Predictions (N) 29 2 0 - 15 1 
False Alarms (N) 600 168 41 43 217 4 
Misses (N) 21 5 8 - 3 0 
Precision  0.05 0.01 0.00 - 0.07 0.20 
Recall  0.58 0.29 0.00 - 0.83 1.00 
TEAMED Patient       
Accurate Predictions (N) 1 0 1 - 0 - 
False Alarms (N) 56 28 10 3 6 0 
Misses (N) 10  5 1 - 2 - 
Precision  0.02 0.00 0.09 - 0.00 - 
Recall  0.09 0.00 0.50 - 0.00 1.00 
 
Sleep 
       
Microsoft Health  
Accurate Predictions (N) 9 0 3 - 2 - 
False Alarms (N) 9 2 0 0 3 0 
Misses (N) 5 4 0 - 1 - 
Precision  0.50 0.00 1.00 - 0.40 - 
Recall  0.70 0.00 1.00 - 0.67 - 
- = No physiological data available for staff –reported episodes of aggression 
 59  
DISCUSSION 
 
This study aimed to provide new insight into the possibility of using data gathered from a 
smartwatch to predict, in advance, aggressive behaviour in an inpatient ABI population via 
machine learning. It was possible to develop both individual and combined models that could 
predict episodes of aggression, however there were a large number of false alarms that meant 
the models lacked clinically utility. 
 
Unanticipated practical and technical problems led to data collection difficulties. The 
cognitive demand of carrying a phone and wearing a smartwatch proved difficult for some 
participants. This meant one device was neglected and data could not be collected and/or 
uploaded. Adverse events unrelated to the study also led to unanticipated data collection 
difficulties, which highlight the ongoing social and emotional difficulties faced by this 
clinical population. Further, relying on the local WiFi connection, where multiple devices 
are competing for access, meant TEAMED Patient data were lost before it could be uploaded. 
In a real-world environment, it is expected these difficulties would have been reduced as 
participants could download the application onto their own phone, which will likely have 
4G capability.  
 
Due to the above difficulties, data analyses were completed with fewer than expected 
episodes of aggression, which contributed to overfitting of the models. The study was also 
limited by the use of a staff-reported measure of challenging behaviour. There were OAS-
MNR aggression reports where staff members’ failed to report a time, therefore 
physiological data will have been labelled incorrectly. Variations in staff threshold for 
reporting aggression, staff time constraints, and relying on staff to be present during all 
episodes, will also have led to under-reporting. Considering the interpersonal nature of 
challenging behaviour, there are likely situations where staff interactions may have 
improved participant arousal thus preventing the aggressive behaviour from occurring. 
Further, previous studies have explored the use of machine learning techniques to identify 
physiological changes associated with fluctuations in self-reported stress levels (Sano et al, 
2018; Umematsu et al, 2018) therefore difficulties with developing a suitable model may 
have been associated with higher arousal levels identified by the algorithm but below the 
threshold of aggressive behaviour reported by staff. This may offer some explanation for the 
high number of false alarms, where participants were able to use self-management, seek 
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support or where staff intervened during these experiences, leading to de-escalation. 
Therefore alternative measures, such as a self-report diary, may have been useful to include 
in addition to staff reporting. 
 
Recommendations 
The following recommendations are proposed:  
Practical Considerations 
• Visual and verbal prompts – incorporating prompts into routine clinical care, e.g. 
personal care, may reduce burden to participants 
• Participant involvement – training the participant to use the applications may help to 
reduce data collection difficulties requiring manual re-synchronisation or Internet 
connection.  
Technical Considerations 
• Available Internet connection – using a phone with 4G access as well as a WiFi 
connection will help reduce missing data 
• Battery life – a long battery life for both the smartwatch and phone will reduce the 
cognitive demands placed on individuals to charge the devices 
• Storage capacity –a large storage capacity would reduce the likelihood of losing data 
during Bluetooth and Internet connection difficulties 
• Computer software – the ability to remotely monitor whether data is being collected from 
technology allows staff to identify when prompting is required 
Other Considerations 
• Self-reported aggression – including self-report measures (e.g. stress, anger) may 
improve the detection of associated physiological changes 
• Adverse event reporting – considering the clinical population and novel nature of the 
study, it is important for future studies to report details of any adverse events via 
appropriate guidelines (e.g. NHS Health Research Authority; 2018) 
 
Future research might also like to explore different algorithms, explore physiological data 
gathered during wake and sleep separately, or compare physical and verbal aggression, or 
aggression severity. For example, the models developed in this study included physiological 
data gathered during sleep as aggressive episodes were also reported overnight. There is 
much research identifying the impact of stress on HRV during sleep (e.g. Brosschot, Van 
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Dijk and Thayer, 2007; Martica et al, 2004), which may have been sufficient for models to 
detect physiological change.  
 
Conclusions 
Being one of a few studies of its kind, this study provides useful considerations for 
conducting research with wearable devices in the ABI inpatient population. Due to the 
unanticipated data collection and aggression reporting difficulties, it is unlikely that the 
current findings truly reflect the applicability of machine learning for the purpose explored 
here. Therefore future research that incorporates the proposed recommendations would offer 
further insight into the possibility of using smartwatch technology and data mining 
approaches for predicting challenging behaviour in the ABI population. 
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Appendix 1.2 Search Strategies 
 
MEDLINE 
1. exp Anoxia/ or anoxia.mp. 
2. exp Brain concussion/ or brain conscussion.mp. 
3. exp Brain edema/ or brain edema.mp. 
4. exp Brain injuries/ or brain injur*.mp. 
5. exp Cerebral Hemorrhage/ or cerebral hemorrhage.mp.  
6. exp Cerebral Hemorrhage, Traumatic/ or cerebral haemorrhage, traumatic.mp. 
7. exp cerebrovascular trauma/ or cerebrovascular trauma.mp. 
8. exp craniocerebral trauma/ or craniocerebral trauma.mp. 
9. exp coma/ or coma.mp. 
10. exp glasgow outcome scale/ or Glasgow outcome scale.mp. 
11. exp glasgow coma scale/ or Glasgow coma scale.mp. 
12. exp Hypoxia, Brain/ or Hypoxia, brain.mp. 
13. exp unconsciousness  or unconsciousness.mp. 
14. exp encephalitis/ or encephaliti*.mp. 
15. exp meningitis/ or meningitis*.mp. 
16. (Glasgow adj (coma or outcome) adj (scale* or score*)).mp. 
17. diffuse axonal injur*.mp. 
18. ((brain* or capitis or cerebr* or crani* or hemispher* or inter-cran* or intra-crani* 
or skull* or head or forebrain or cerebellar or brainstem or vertebrobasilar) adj3 
(contusion* or bleed* or hemorrhag* or haemorrhag* or haematoma* or hematoma* 
or apoplexy or emboli* or pressure or damag* or fractur* or injur* or trauma* or 
wound* or aneurysm* or anoxi* or hypoxi* or ischaem* or ischem* or thrombo* or 
oedema or edema or swell*)).mp. 
19. or/1-18 
20. exp Neurofeedback/ or neurofeedback.mp. 
21. neurotherapy.mp. 
22. exp Biofeedback, Psychology/ or biofeedback.mp. 
23. or/20-22 
24. 19 and 23 
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EMBASE 
1. exp Anoxia/ or anoxia.mp. 
2. exp Brain concussion/ or brain conscussion.mp. 
3. exp Brain edema/ or brain edema.mp. 
4. exp Brain injury/ or brain injur*.mp. 
5. exp BrainHemorrhage/ or brain hemorrhage.mp.  
6. exp Traumatic brain injury/ or traumatic brain injury.mp. 
7. expHead Injury/ or head injury.mp. 
8. exp coma/ or coma.mp. 
9. exp glasgow outcome scale/ or Glasgow outcome scale.mp. 
10. exp glasgow coma scale/ or Glasgow coma scale.mp. 
11. exp Brain hypoxia/ or brain hypoxia.mp. 
12. exp unconsciousness  or unconsciousness.mp. 
13. exp encephalitis/ or encephaliti*.mp. 
14. exp meningitis/ or meningitis*.mp. 
15. (Glasgow adj (coma or outcome) adj (scale* or score*)).mp. 
16. diffuse axonal injur*.mp. 
17. ((brain* or cerebr* or crani* or hemispher* or inter-cran* or intra-crani* or skull* or 
head or forebrain or cerebellar or brainstem or vertebrobasilar) adj3 (contusion* or 
bleed* or hemorrhag* or haemorrhag* or haematoma* or hematoma* or apoplexy or 
emboli* or pressure or damag* or fractur* or injur* or trauma* or wound* or 
aneurysm* or anoxi* or hypoxi* or ischaem* or ischem* or thrombo* or oedema or 
edema or swell*)).mp. 
18. or/1-17 
19. exp Neurofeedback/ or neurofeedback.mp. 
20. (neurotherapy or EEG feedback).mp. 
21. exp feedback system or biofeedback.mp. 
22. or/19-21 
23. 18 and 22 
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PsycINFO Search Strategy  
1. SU Anoxia or KW anoxia 
2. SU Brain concussion or KW brain concussion 
3. SU Brain edema or KW brain edema 
4. SU Brain injury or KW brain injur* 
5. SU Brain Hemorrhage or KW brain hemorrhage 
6. SU Traumatic Brain Injury or KW traumatic brain injury 
7. SU Head Injury or KW head injury 
8. SU Cerebral Hemorrhage or KW cerebral hemorrhage 
9. SU cerebrovascular accident or KW cerebrovascular accident 
10. SU craniocerebral trauma or KW craniocerebral trauma 
11. SU coma or KW coma 
12. SU glasgow outcome scale or KW Glasgow outcome scale 
13. SU glasgow coma scale or KW Glasgow coma scale 
14. SU hypoxic brain injury or KW hypoxia brain injury 
15. SU unconsciousness or KW unconsciousness 
16. SU encephalitis or KW encephaliti* 
17. SU meningitis or KW meningitis* 
18. KW (Glasgow adj (coma or outcome) adj (scale* or score*)) 
19. KW diffuse axonal injur* 
20. KW ((brain* or capitis or cerebr* or crani* or hemispher* or inter-cran* or intra-
crani* or skull* or head or forebrain or cerebellar or brainstem or vertebrobasilar) 
adj3 (contusion* or bleed* or hemorrhag* or haemorrhag* or haematoma* or 
hematoma* or apoplexy or emboli* or pressure or damag* or fractur* or injur* 
or trauma* or wound* or aneurysm* or anoxi* or hypoxi* or ischaem* or 
ischem* or thrombo* or oedema or edema or swell*)) 
21. or/1-20 
22. SU Neurofeedback or KW neurofeedback 
23. SU neurotherapy or KW neurotherapy 
24. SU biofeedback or SU biofeedback therapy or KW biofeedback 
25. or/22-24 
26. 21 and 25 
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CENTRAL 
1. MeSH descriptor: [Hypoxia] explode all trees 
2. MeSH descriptor: [Brain Concussion] explode all trees 
3. MeSH descriptor: [Brain Edema] explode all trees 
4. MeSH descriptor: [Brain Injuries] explode all trees 
5. MeSH descriptor: [Intracranial Hemorrhages] explode all trees 
6. MeSH descriptor: [Craniocerebral Trauma] explode all trees 
7. MeSH descriptor: [Cerebral Hemorrhage] explode all trees 
8. MeSH descriptor: [Unconsciousness] explode all trees 
9. MeSH descriptor: [Glasgow Outcome Scale] explode all trees 
10. MeSH descriptor: [Glasgow Coma Scale] explode all trees 
11. MeSH descriptor: [Hypoxia, Brain] explode all trees 
12. MeSH descriptor: [Encephalitis] explode all trees 
13. MeSH descriptor: [Meningitis] explode all trees 
14. ((brain* or capitis or cerebr* or crani* or hemispher* or inter-cran* or intra-crani* 
or skull* or head or forebrain or cerebellar or brainstem or vertebrobasilar) next/3 
(contusion* or bleed* or hemorrhag* or haemorrhag* or haematoma* or hematoma* 
or apoplexy or emboli* or pressure or damag* or fractur* or injur* or trauma* or 
wound* or aneurysm* or anoxi* or hypoxi* or ischaem* or ischem* or thrombo* or 
oedema or edema or swell*)):ti,ab,kw (Word variations have been searched) 
15. (Glasgow next (coma or outcome) next (scale* or score*)):ti,ab,kw (Word 
variations have been searched) 
16. "unconsciousness" or "diffuse axonal injur*" or "encephaliti*" or 
"meningiti*":ti,ab,kw (Word variations have been searched) 
17. MeSH descriptor: [Biofeedback, Psychology] explode all trees 
18. "neurofeedback" or "neurotherapy" or "biofeedback":ti,ab,kw (Word variations 
have been searched) 
19. {or #1-#16} 
20. {or #17-#18} 
21. #19 and #20 
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ClinicalTrials.gov 
 
Conditions: Brain Injury 
Interventions: neurofeedback OR neurotherapy OR biofeedback 
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Appendix 1.3 Clinical Trials Assessment Measure (CTAM) 
Trial design 
area 
Item Score 
Sample 
two questions: 
maximum score 
= 10 
Q1: is the sample a convenience sample (score 2)  
or a geographic cohort (score 5),  
or highly selective sample, e.g., volunteers (score 0) 
Convenience sample—e.g., clinic attenders, referred 
patients or Geographic cohort—all patients eligible in a 
particular area 
 
Q2: is the sample size greater than 27 participants in each 
treatment group (score 5) or based on described and 
adequate power calculations (score 5) 
 
Allocation 
three questions: 
maximum score 
= 16 
 
Q3: is there true random allocation or minimisation 
allocation to treatment groups (if yes score 10) 
 
Q4: is the process of randomisation described (score 3)  
Q5: is the process of randomisation carried out 
independently from the trial research team (score 3) 
 
Assessment (for 
the main 
outcome) 
five questions: 
maximum score 
= 32 
 
Q6: are the assessments carried out by independent assessors 
and not therapists (score 10) 
 
Q7: are standardised assessments used to measure 
symptoms in a standard way (score 6),  
idiosyncratic assessments of symptoms (score 3) 
 
Q8: are assessments carried out blind (masked) to treatment 
group allocation (score 10) 
 
Q9: are the methods of rater blinding adequately described 
(score 3) 
 
Q10: is rater blinding verified (score 3)  
Control groups 
one question: 
maximum score 
= 16 
Q11: TAU is a control group (score 6)  
and/or a control group that controls for non-specific effects 
or other established or credible treatment (score 10) 
 
Analysis 
two questions: 
maximum score 
= 15 
 
Q12: the analysis is appropriate to the design and the type of 
outcome measure (score 5) 
 
Q13: the analysis includes all those participants as 
randomised (sometimes referred to as an intention to treat 
analysis) (score 6) and an adequate investigation and 
handling of drop outs from assessment if the attrition rate 
exceeds 15% (score 4) 
 
Active 
treatment 
two questions: 
maximum score 
= 11 
Q14: was the treatment adequately described (score 3)  
and was a treatment protocol or manual used (score 3) 
 
Q15: was adherence to the treatment protocol or treatment 
quality assessed (score 5) 
 
Total score =  
Where the criterion is not reached for any question score = 0, Total maximum score = 100 
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Appendix 1.4 Reasons for Excluded Full-Text Articles  
 
Study Reason for Exclusion 
Ayers 1999 Review 
Ayers 2006 Review and Case Studies 
Burke et al 1991 Case Study Design 
Keller & Rottensteiner 2000 No between group comparisons completed 
Keller 2001 No between group comparisons completed 
Manko et al 2013 No between group comparisons completed 
Schoenberger et al 2001 Involuntary modulation neurofeedback protocol 
Thornon & Carmody 2013 Normative reference group used as control group 
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Ayers, Margaret E. All-Digital, Real-Time EEG Feedback with Open and Closed Head 
Trauma. In G.J Murrey (Eds.), Alternate Therapies in the Treatment of Brain Injury and 
Neurobehavioral Disorders. New York: Haworth Press, pp. 135-147 
 
Burke, W.H., Zencius, A.H., Wesolowski, M.D. & Doubleday, F. (1991). Improving 
executive function disorders in brain-injured clients. Brain Injury, 5(3), 241-252. 
 
Keller, I. & Rottensteiner, B. (2000). Neurofeedback in closed head injury. Neurologie und 
Rehabilitation, 6, 71-76. 
 
Keller, I. (2001). Neurofeedback therapy of attention deficits in patients with traumatic brain 
injury. Journal of Neurotherapy, 5(1-2), 19-32. 
 
Mańko, G., Olszewski, H., Krawczyński, M. & Tłokiński, W. (2013). Evaluation of 
differentiated neurotherapy programs for patients recovering from severe TBI and long term 
coma. Acta Neuropsychologica, 11(1). 
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neurotherapy system in the treatment of traumatic brain injury: An initial evaluation. The 
Journal of head trauma rehabilitation, 16(3), pp.260-274. 
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 83  
Appendix 1.5 Summary of Means, Standard Deviations (SD) and Effect Sizes (ES) 
Reddy et al 2013(n = 60) 
Neurofeedback Group Control Group ES (Cohen’s d)b 
Pre- Post- Mean Diff Pre- Post- Mean Diff Post-
Interve
ntion 
Means 
Mean 
Diffs 
Mean(SD) Mean(SD)a 
 
Mean(SD) Mean(SD) Mean(SD)a 
 
Mean(SD) 
Cognition  After 3-5 weeks   After 1 month   
Finger Tapping (sec) Right 40.07(13.44) 47.57(7.45)** -7.50(10.79) 44.59(8.64) 44.63(10.08)NS -0.03(6.81) 0.33 0.83  
Left 37.46(11.80) 42.04(7.97)** -4.58(9.73) 40.18(9.95) 40.31(11.22)NS -0.13(5.84) 0.18 0.55  
DSST (sec) 
 
327.41 
(194.87) 
302.24 
(173.09)** 
25.17 
(176.65) 
402.21 
(249.05) 
350.41 
(159.84)NS 
51.79 
(163.70) 
0.29 
 
0.16  
Digit Vigilance Test (sec) 
 
685.59 
(346.54) 
564.48 
(256.23)** 
121.10 
(304.16) 
699.41 
(279.89) 
665.24 
(280.32)NS 
34.17 
(146.59) 
0.38 
 
0.36  
Animal Names Test 18.50(54.66) 35.23(133.53)** -16.73(147.19) 10.13(3.81) 10.17(3.26)NS -0.03(2.85) 0.27 0.16  
Working Memory 1Back Hits 7.73(2.43) 8.20(1.86)* -0.47(1.53) 7.83(1.76) 8.13(1.11)NS -0.30(1.82) 0.05 0.10 
  2Back Hits 4.63(2.67) 6.83(1.84)** -2.20(2.40) 5.70(2.07) 5.33(2.09)NS 0.37(2.37) 0.76 1.08  
Tower of London Test 6.87(3.52) 9.20(1.81)** -2.33(3.58) 8.59(2.51) 8.45(2.40)NS 0.14(2.61) 0.35 0.79  
WCST Perseverative Errors 41.47(34.53) 19.80(16.18)** 21.67(34.43) 38.90(27.71) 35.97(20.78)NS 2.93(28.47) 0.87 0.59 
Conceptual Level  
               Responses 
36.77(24.97) 
 
56.40(16.11)** 
 
-19.63(25.03) 33.66(19.59) 
 
39.34(17.80)NS 
 
-5.69(19.20) 1.00 
 
0.63 
Stroop Test (sec) 
 
159.83 
(138.10) 
124.93 
(86.74)** 
34.90 
(109.42) 
138.43 
(120.97) 
127.39 
(124.20)NS 
11.04 
(110.73) 
0.02 
 
0.22 
Token Test 28.47(9.13) 34.30(2.44)** -5.83(7.51) 32.17(3.69) 32.07(4.19)NS 0.10(3.17) 0.65 1.03 
AVLT  Total 31.27(13.97) 48.83(11.86)** -17.57(9.95) 38.30(13.35) 43.43(15.56)* -5.13(9.19) 0.39 1.30 
           Immediate Recall 6.23(3.77) 10.60(3.62)** -4.37(2.87) 8.87(3.48) 8.87(3.79)* 0.00(2.52) 0.47 1.62 
           Delayed Recall 5.80(3.64) 10.33(3.80)** -4.53(2.84) 8.33(3.44) 8.90(3.56)* -0.57(2.22) 0.39 1.56 
CFT    Copy 28.40(11.89) 33.90(4.51)** -5.50(9.55) 30.97(6.23) 31.86(3.90)* -0.90(3.94) 0.48 0.63 
           Immediate Recall 12.67(8.41) 22.10(9.58)** -9.43(7.30) 15.90(8.16) 19.72(7.93)NS -3.83(7.40) 0.27 0.76 
           Delayed Recall 13.07(8.42) 22.40(9.22)** -9.33(8.37) 16.52(8.13) 19.03(8.19)NS -2.52(6.40) 0.39 0.92 
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continued         
Post-Concussion Symptoms        
Visual Analog Scale 7.87(2.22) 2.83(2.13)** -5.03(1.49) 6.20(3.02) 5.77(3.07)* -0.43(1.33) 1.11 3.25 
RHIFQ 30.20(7.59) 13.20(7.85)** -17.00(8.82) 26.57(10.29) 22.27(10.15) NS -4.30(8.72) 1.00 1.47 
RPQ 41.33(9.80) 12.90(7.02)** -28.43(9.09) 38.40(11.94) 35.33(12.62) -3.06(9.06) 2.10 2.79 
Quality of Life Scale         
   Physical  17.00(3.42) 22.90(2.02)** 5.90(3.88) 19.67(3.19) 19.77(3.52)* 0.10(3.49) 1.09 1.57 
           Psychological 15.17(3.05) 19.10(1.82)** 3.93(2.49) 16.73(2.59) 17.27(3.23)NS 0.53(2.90) 0.70 1.25 
           Social 8.47(1.97) 10.47(0.97)** 2.00(1.76) 8.97(1.45) 9.33(1.47)NS 0.36(1.62) 0.92 0.96 
           Environmental 28.00(5.11) 30.77(2.81)** 2.76(4.26) 27.80(3.56) 27.80(3.38)NS 0.00(3.09) 0.96 0.75 
           Total 68.63(11.85) 83.23(5.68)** 14.60(10.01) 73.16(8.38) 74.16(9.28)NS 1.0(8.90) 1.18 1.43 
Rostami et al 2017 (n = 13)         
Cognition  After 4 weeks   After 4 weeks     
WMS-IV Memory quotient  84.83(23.02) 87.66(16.44)NS 2.83(11.50) 79.40(13.42) 88.60(23.07)NS 9.2(11.08) 0.05 0.56NS 
General info 3.75(1.38) 4.50(1.30)NS 0.75(1.16) 4.20(1.78) 4.80(2.16)NS 0.60(1.94) 0.17 0.09NS 
Orientation 3.75(1.58) 4.25(0.88)NS 0.50(1.06) 4.00(1.22) 4.20(1.78)NS 0.20(0.83) 0.04 0.32NS 
Learning association 12.75(5.46) 15.00(4.65)NS 2.25(2.95) 11.60(3.59) 15.60(4.56)* 4.00(2.26) 0.13 0.67NS 
Mind control 3.87(3.31) 3.75(2.60)NS -0.12(1.88) 4.80(2.28) 4.80(2.04)NS 0.00(1.87) 0.45 0.06NS 
Logical memory 6.68(2.75) 2.75(0.97)NS 0.56(2.14) 6.00(2.97) 4.18(1.87)NS 0.00(1.45) 0.96 0.31NS 
Repeat numbers 8.62(1.92) 8.50(1.51)NS -0.12(1.35) 8.20(0.44) 8.00(2.00)NS -0.20(2.38) 0.28 0.04NS 
Visual memory 7.12(3.64) 3.58(1.26)NS 1.37(3.62) 9.60(1.51) 2.16(0.96)NS 0.60(1.67) 1.27 0.27NS 
DUAF     Correct answers -. 38.42(-.)NS -1.14(7.74) -. 51.40(-.)* 10.00(7.74) -. 1.44* 
Reaction time -. 49.00(-.)NS 1.85(16.05) -. 50.00(-.)NS 11.20(12.19) -. 0.66 NS 
Incorrect answers 
 
-. 51.80(-.)* 
-15.28 
(139.15) 
 
-. 44.57(-.)NS 36.80(25.40) 
 
-. 0.52 NS 
Tinius and Tinius 2001(n = 31)       
Cognition         
IVA CPT         
Full Scale Attention Q 74.30(27.30) 97.10(19.30)* 5.90(-.) 100.70(8.90) 104.30(11.00)NS 3.60(-.) 0.46 -. 
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continued         
Full Scale Response Q 91.20(19.90) 104.70(9.10)* 13.50(-.) 117.60(11.00) 112.20(12.40)NS -5.40(-.) 0.69 -. 
Attention Q              Auditory 75.70(27.60) 94.70(13.40)* 19.00(-.) 102.00(9.30) 104.80(10.60)NS 2.80(-.) 0.84 -. 
Visual 77.00(29.50) 97.80(19.90)* 20.80(-.) 98.70(13.10) 103.20(12.50)NS 4.50(-.) 0.32 -. 
Response control Q Auditory 90.70(20.90) 103.80(10.60)* 13.10(-.) 115.30(8.70) 108.80(10.60)NS -6.50(-.) 0.47 -. 
                                 Visual 93.20(14.60) 106.90(10.40)* 13.70(-.) 117.10(11.0) 113.50(14.80)NS -3.60(-.) 0.52 -. 
Prudence                 Auditory 91.70(23.80) 103.10(10.20)NS 11.40(-.) 107.00(6.50) 105.70(9.10)NS -1.30(-.) 0.27 -. 
                                 Visual 91.50(15.90) 100.70(14.30)* 9.20(-.) 105.30(6.90) 106.50(8.40)NS 1.20(-.) 0.49 -. 
Consistency             Auditory 87.50(18.30) 97.60(12.00)* 10.10(-.) 111.50(10.70) 108.00(10.80)NS -3.5(-.) 0.91 -. 
                                 Visual  98.70(12.90) 111.60(13.50)* 12.90(-.) 115.20(17.70) 116.10(16.20)NS 0.90(-.) 0.30 -. 
Comprehension       Auditory 72.80(38.70) 103.00(10.20)* 30.20(-.) 105.70(6.90) 103.10(11.90)NS -2.60(-.) 0.01 -. 
                                 Visual 70.20(39.80) 106.80(4.70)* 36.60(-.) 106.70(4.10) 103.20(7.70)NS -3.5(-.) 0.56 -. 
WCST Number of trials 
 
107.90 
(21.60) 
89.00(19.70)* 
 
-18.90(-.) 85.90(16.90) 
 
88.50(19.10)NS 
 
2.90(-.) 0.03 -. 
Perseverative errors 22.60(9.20) 10.40(9.20)* -12.20(-.) 8.50(6.40) 7.80(5.40)NS -0.70(-.) 0.34 -. 
Post-Concussion Symptoms        
Inconsistency 7.90(3.60) 5.00(2.30)* -2.90(-.) 3.70(2.60) 3.80(2.80)NS 0.10(-.) 0.47 -. 
General measure of 
impairment 
147.00 
(44.90) 
107.60(57.60)* 
 
-39.40(-.) 46.70(30.80) 
 
44.10(29.00)NS 
 
-2.60(-.) 1.39 -. 
Total items checklist 60.70(10.00) 53.70(15.40)* -7.00(-.) 31.10(16.60) 32.90(19.30)NS 1.80(-.) 1.19 -. 
Attention 22.40(6.80) 15.80(8.40)* -6.60(-.) 8.70(7.50) 7.50(6.20)NS -1.20(-.) 1.12 -. 
Language-verbal learning 12.90(4.90) 8.40(6.20)* -4.50(-.) 2.70(2.60) 3.50(2.80)NS 0.80(-.) 1.02 -. 
Academic problems 18.80(7.00) 18.60(16.30)* -0.20(-.) 6.40(4.30) 7.70(5.20)NS 1.30(-.) 0.90 -. 
* = p<0.05, ** = p <0.01, NS = Not significant; a = compared to baseline, b = compared to control group; -. = value could not be calculated 
Abbreviations: AVLT = Auditory Verbal Learning Test; CFT = Complex Figure Test; DSST= Digit Symbol Substitution Test; DUAF = unreferenced attention 
test; ES= Effect Size; IVA CPT  = Intermediate Visual and Auditory Continuous Performance Test; NIMHN= National Institute of Mean Health and 
Neurosciences; NIS  = Neuropsychological Impairment Scales; NFB= Neurofeedback; Q  = Quotient; RHIFQ = Rivermead Head Injury Follow-up 
Questionnaire; RPQ= Rivermead Post Concussion Symptoms Questionnaire; TAU = Treatment as Usual; WAIS-R = Wechsler Adult Intelligence Scale – 
Revised; WCST = Wisconsin Card Sorting Test 
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32 Market Place 
Burgess Hill 
West Sussex 
RH15 9NP 
Tel: 01444 239123 
Fax: 01444 244978 
                                                        Email: info@thedtgroup.org 
Dr Brian O’Neill 
Graham Anderson House 
1161 Springburn Road 
G21 1UU 
5th December 2017 
Dear Dr O’Neill, 
 
THE DISABILITIES TRUST RESEARCH ETHICS COMMITTEE (DTREC) APPROVAL 
 
Study Title: Technology Evaluating And Measuring Emotional Dysregulation 
(TEAMED). 
 
We are pleased to inform you that the DTREC has APPROVED an extension of the 
abovementioned project, and the addition of Ms Julia Day as an investigator in the project. 
 
The revised approval period is from December 2017 to July 2018.  
 
The following are to be observed upon DTREC approval: 
  
1) The study will be conducted in accordance with Trust’s relevant policies. 
2) Service users who lack capacity to consent to take part in research may NOT be 
approached for recruitment into the study, and consent may NOT be given by a proxy 
(e. g. relative).  
3) The Researcher should promptly report the DTREC of: 
 i. Deviations from, or changes to the protocol. 
ii. New information that may affect adversely the risk to the participants or the 
conduct of the study. 
iii. Change in planned timeline of the study 
iv. Completion of the study. 
3) A Study Status Report should be submitted for the following: 
i. Study status: a brief report is to be submitted within six months of 
commencement of the study. 
ii. Study completion or termination: the Final Report is to be submitted within 
three months of study completion or termination. 
4) Any dissemination of the findings should acknowledge the support of the Brain Injury 
Rehabilitation Trust and The Disabilities Trust in the study. 
 
On behalf of the DTREC, I would like to wish you the best with your study. 
 
Yours sincerely, 
 
p. p.  
 
Dr Caroline Drugan 
Chair of the DTREC 
32 Market Place 
Burgess Hill 
RH15 9NP 
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32 Market Place 
Burgess Hill 
West Sussex 
RH15 9NP 
Tel: 01444 239123 
Fax: 01444 244978 
  Email: info@thedtgroup.org 
Dr Brian O’Neill 
Graham Anderson House 
1161 Springburn Road 
G21 1UU 
19th March 2018 
Dear Dr O’Neill, 
THE DISABILITIES TRUST RESEARCH ETHICS COMMITTEE (DTREC) APPROVAL 
Study Title: Technology Evaluating And Measuring Emotional Dysregulation 
(TEAMED). 
We are pleased to inform you that the DTREC has APPROVED an extension of the 
abovementioned project, and the addition of Ms Julia Day as an investigator in the project. 
The revised approval period is from 6th December 2017 to 18th September 2018. 
The following are to be observed upon DTREC approval: 
1) The study will be conducted in accordance with Trust’s relevant policies.
2) Service users who lack capacity to consent to take part in research may NOT be
approached for recruitment into the study, and consent may NOT be given by a proxy
(e. g. relative).
3) The Researcher should promptly report the DTREC of:
i. Deviations from, or changes to the protocol.
ii. New information that may affect adversely the risk to the participants or the
conduct of the study.
iii. Change in planned timeline of the study
iv. Completion of the study.
3) A Study Status Report should be submitted for the following:
i. Study status: a brief report is to be submitted within six months of
commencement of the study.
ii. Study completion or termination: the Final Report is to be submitted within
three months of study completion or termination.
4) Any dissemination of the findings should acknowledge the support of the Brain Injury
Rehabilitation Trust and The Disabilities Trust in the study.
On behalf of the DTREC, I would like to wish you the best with your study. 
Yours sincerely, 
Dr Caroline Drugan 
Chair of the DTREC 
32 Market Place 
Burgess Hill 
RH15 9NP 
p. p.
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18/NS/0030:  Please quote this number on all correspondence 
 
Yours sincerely 
 
 
pp’d on behalf of 
Dr Hanne Bruhn 
Alternate Vice-Chair 
 
 
 
Enclosures: List of names and professions of members who took part in the 
review 
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Appendix 2.2 Participant Information Sheets
Version	1.1	07.05.18	
 
 
 
Participant Information Sheet 
Technology Evaluation and Measuring Emotional Dysregulation (TEAMED) 
 
You have been invited to take part in a research study. Before you decide whether to 
take part, it is important to understand why we are doing the research and what it 
will involve. Please read this information carefully and take time to decide. Discuss it 
with someone if you would like. Please ask if you would like more information.  
 
What is the purpose of the study? 
The study aims to understand how body functions (e.g. temperature, heart rate) can 
influence people’s ability to manage emotions and behaviour. Strong emotions can 
lead to behaviour that can harm us or others, such as hurting yourself and others, 
and damaging things. We are aiming to see whether our body functions help to 
predict harmful behaviour.  
 
What is the procedure that is being tested? 
We are testing whether a smartwatch with special software can predict harmful 
behaviour. The smartwatch collects information about heart rate, sweat, 
temperature and movement. The system will then create a calculation that can 
predict when this information will lead to harmful behaviour.  
 
Why have I been invited? 
You have been chosen to participate as you have experienced a severe brain injury 
and sometimes have difficulty with controlling emotions and behaviour.  
 
Do I have to take part? 
No. It is up to you whether you decide to take part or not. If you decide to take part, 
you are free to withdraw from the study at any time and you do not have to give a 
reason. If you decide not to take part, this will not affect the care you receive. 
 
What will happen to me if I take part? 
A member of the research team will ask you to wear a watch for up to 12 weeks. 
During this time, the watch will collect information about your heart rate, sweat, 
temperature and movement. You will also be given a phone, which will store this 
information. You will be asked to take off the watch when you shower, and the 
medical staff can help remind you to do this. You will not be asked to do anything 
else. Information from your medical record such as your age, gender and medical 
information will also be collected. 
 
What are the alternatives for treatment? 
If you chose not to take part, you will not be asked to wear the watch and your care 
will continue as usual.   
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What are the possible disadvantages and risks of taking part? 
There is a small chance that you might have a skin reaction to the watchstrap. If this 
happens, please let a medical staff member know and they can treat the skin 
reaction. You will not be asked to continue wearing the watch and your participation 
in the study will end. 
 
What are the possible benefits of taking part? 
There are no known benefits. 
 
What happens when the research stops? 
At the end of the research, you will not be asked to continue wearing the watch. 
 
Will my taking part in this study be kept confidential? 
All information collected during the study will be strictly confidential, including 
information gathered from your medical file. You will not be identifiable from the 
information gathered about you. This information will be anonymised and stored on 
Brain Injury Rehabilitation Trust, University of Stirling and University of Glasgow 
computers, accessible by the research team. 
 
What will happen to the results and data of the study? 
The data from the study will be stored anonymously and securely on Brain Injury 
Rehabilitation Trust, University of Stirling and University of Glasgow computers for 
up to 10 years and may be used in future approved studies if you agree to this. The 
results of the study will form part of an educational qualification and may be 
published in a specialist journal within two years of the study finishing. You will not 
be identifiable in any report. The care team may inform you of any results if you 
wish. 
 
Complaints 
If you have any complaints about the study, please speak to Sandra Wylie (Service 
Manager, Brain Injury Rehabilitation Trust), Graham Anderson House, 1161 
Springburn Road, Glasgow, G21 1UU. Tel: 0141 4046060. 
 
Who is organising and funding the research? 
University of Glasgow and the Brain Injury Rehabilitation Trust is organising and 
funding the research. 
 
Who has reviewed the study? 
Independent researchers at the University of Glasgow have reviewed the study. The 
NHS North of Scotland (2) Research Ethics Committee approved the study. 
 
Contacts for Further Information 
Julia Day (Trainee Clinical Psychologist) j.day.1@research.gla.ac.uk 
Brian O’Neill (Consultant in Neuropsychology and Rehabilitation) 
Brian.ONeill@thedtgroup.org 
 
Thank you for taking the time to read this information.  
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Participant Information Sheet (Easy Read) 
Technology Evaluating and Measuring Emotional 
Dysregulation (TEAMED) 
 
You have been invited to take part in a study. Before you 
choose whether to take part, please read this information. 
Please talk about it to the person who has given you this 
information.  
 
What is the study for? 
The study is to help our understanding of difficulty controlling 
emotions and behaviour after a brain injury.  
 
Difficulty controlling emotions can lead to situations where you 
may hurt yourself or others, damage things, or do things that 
make it difficult for others to support you.  
 
Why have I been invited? 
You have been chosen as you have injured your brain and have 
difficulty with managing emotions after your brain injury.  
 
Do I have to take part? 
No. It is up to you whether you decide to take part. You can 
stop taking part at any time and you do not have to give a 
reason. This will not affect the care you receive. 
 
What will happen to me if I take part? 
You will be asked to wear a watch for 8 weeks. During this time 
the watch will collect information about your heartbeat, 
temperature, sweat and movement. You will also be given a 
phone, which will store the information.  
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You will be asked to take off the watch when you shower, and 
the medical staff can help remind you to do this. You will not be 
asked to do anything else. Information from your medical 
record such as your age, gender and medical information will 
also be collected. 
 
What is being tested? 
We are finding out whether information collected on the watch 
helps predict people’s behaviours.  
 
What if I don’t take part? 
No. If you choose not to take part, the staff team will help you 
in the same way as normal.  
 
What are the possible risks of taking part? 
There is a small chance that you may have a skin reaction to the 
watchstrap. If this happens, please let your medical staff know. 
You will then stop taking part in the study. 
 
What are the possible benefits of taking part? 
There are no known benefits.  
 
What happens when the research stops? 
You will not be asked to keep using the watch.  
 
Who will know about me taking part? 
All information collected during the study will be strictly 
confidential. You will not be identifiable from the information 
gathered about you. 
 
What will happen to the results and data of the study? 
The data from the study will be stored securely for up to 10 
years and may be used in future studies if you agree to this.  
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The results of the study will be used for an educational degree 
and may be published in a specialist journal within two years of 
the study finishing. You will not be identifiable in any report.  
 
Complaints 
If you have any complaints about the study, your staff team will 
help you speak to Sandra Wylie (Service Manager, Brain Injury 
Rehabilitation Trust). 
 
Who is organising and funding the research? 
University of Glasgow and the Brain Injury Rehabilitation Trust 
is organising and funding the research. 
 
Who has reviewed the study? 
The University of Glasgow have reviewed the study. The NHS 
North of Scotland (2) Research Ethics Committee approved the 
study. 
 
Contacts for Further Information 
If you would like more information, your staff team will help 
you speak to Brian O’Neill (Consultant in Neuropsychology and 
Rehabilitation).  
 
Thank you for taking the time to read this information.  
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1    IRAS Project ID: 243255   Version 1.1 (07.05.18) 
  
                                                                                                            
CONSENT 
FORM 
Technology Evaluating And Measuring Emotional Dysregulation 
(TEAMED) 
Please Initial 
 
1. I confirm that I have read and understand the information leaflet dated 07.05.18 
(version 1.1), or easy-read information leaflet dated 28.02.18 (version 1), for the 
above study. 
 
2. I confirm that the researcher has answered any queries to my satisfaction.  
 
3. I understand that my participation is voluntary and that I am free to withdraw from 
the project at any time, without having to give a reason and that if I withdraw my 
medical care will not be affected. 
 
 
4. I understand that any information collected about me in the study will remain 
confidential, and that no information which identifies me will be made publicly 
available.  
 
5. I give permission for the research team to access my medical records at Graham 
Anderson House to obtain information which is relevant to this study. 
 
6. I understand that my data (including personal information) may be accessed by 
authorised representatives of the University of Glasgow (the Sponsor) for the 
purposes of audit only. 
 
7. I consent to taking part in this study. 
 
 
 
------------------------------------------               --------------------         ------------------------------------- 
Name of Participant           Date      Signature 
 
------------------------------------------               --------------------          ------------------------------------ 
Name of Researcher           Date       Signature 
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Appendix 2.4 Example of Challenging Behaviour Tool Incorporating Overt 
Aggression Scale-Modified for Neurorehabilitation (OAS-MNR) 
 
Behaviour Recording for  
 
Salutogenic Behaviours  
 Date / Time / How often? 
(Best guess) 
How good did it appear to feel? 
(Bigger the smiley, the better the 
feeling) 
Helped someone out  
☺      ☺      ☺ 
Appeared angry, or aggressive, but got over it  
☺      ☺      ☺ 
Enjoyed the moment / Engaged in relaxation  
☺      ☺      ☺ 
Finished a task or job  
☺      ☺      ☺ 
Cooked a meal for themselves  
☺      ☺      ☺ 
Cooked a meal for others  
☺      ☺      ☺ 
Phoned/met a friend  
☺      ☺      ☺ 
Solved a problem  
☺      ☺      ☺ 
Did some exercise  
☺      ☺      ☺ 
Spent time outdoors  
☺      ☺      ☺ 
Lost themselves in something fun  
☺      ☺      ☺ 
…  
☺      ☺      ☺ 
 
Challenging Behaviours 
Date / 
Time 
Staff 
Initials 
Antecedents Behaviour 
(type, 
rating) 
Interventions 
(A-l) 
Multiple Recordings 
(  when multiple 
identical incidents take 
place in quick 
succession < 2 second 
interval) 
Contributing Factors Observed 
directly 
beforehand 
(1-25) 
Structured 
activity 
Noisy 
environment 
        
        
        
        
        
        
        
        
        
        
        
        
        
        
        
*NB each separate incident recorded in this way must be separated by at least 2 seconds 
 
Name 
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1. Aggressive Behaviours (From the Modified Overt Aggression Scale – MOAS) 
 Verbal aggression - VA Physical aggression against 
objects - PO 
Physical aggression 
against self- PS 
Physical aggression against 
other people - PP 
1 Makes loud noises, shouts angrily, is 
not person directed e.g ‘bloody hell’ 
Slams doors, scatters clothing, 
makes a mess in response to 
clear antecedent (without others 
being at risk of being hit). 
Picks/scratches skin, hits self, 
pulls hair (with no/minor 
injury). 
Threatening gesture clearly 
person directed, swings at 
people, grabs clothes, spitting 
at people. 
2 Mild personal insults clearly directed 
at some other person, not including 
swearing/offensive sexual 
comments e.g ‘you are a stupid 
idiot’. 
Throws objects down, kicks 
furniture without breaking it, 
marks the wall. 
Bangs head, hits fist into 
object, throws self onto floor 
or into objects (hurts self 
without serious injury). 
Strikes, kicks, pushes, pulls hair 
(without significant injury). 
3 Swearing, moderate threats clearly 
person directed at others or self e.g 
‘fuck off you bastard’. 
Breaks objects, smashes 
windows. 
Inflicts small cuts, bruises, 
minor burns to self. 
Attacks others causing mild-
moderate physical injury, 
(bruises, sprains, welts). 
4 Clear threats of violence directed at 
others or self e.g ‘I’m going to kill 
you’. 
Sets fire, throws objects 
dangerously (some other person 
is at risk of being hit, regardless 
of intention). 
Mutilates self, causes deep 
cuts, bites that bleed, internal 
injury, fracture, loss of 
consciousness. 
Causes severe physical injury 
(broken bones, internal injury) 
to person aggression directed. 
 
2. Sexualised Behaviours (From the Saint Andrews-Swansea Sexualized Behaviour Assessment – SASBA) 
 Verbal Comments 
VC 
Non Contact 
NC 
Exposure 
E 
Touching Others 
TO 
1 Intimate personal comments of mild 
severity, e.g ‘have you got a 
girlfriend?’, ‘I love you’, You’re 
gorgeous’. 
Blowing kisses, kissing self or 
staring at another persons groin, 
female breasts or buttocks, or 
makes obscene gesture. 
Appears unaware that is 
exposing genitals, female 
breasts or buttocks in a public 
setting. 
Touches for a prolonged 
period (excess of 2 seconds) or 
strokes another person – does 
not include groin, female 
breasts or buttocks. 
2 Comments of a sexual nature, 
clearly not person directed, e.g ‘I’ve 
got a big dick’. 
Touches own groin, female 
breasts or buttocks over or under 
clothes (no exposure). 
Wearing no clothes in a 
public setting, clearly not 
person directed. 
Kissing another person. 
3 Descriptions of another persons 
groin, female breasts or buttocks 
clearly directed to another person 
e.g ‘You have a nice bottom’.  ‘She’s 
got lovely breasts’. 
Masturbates in a non shared 
setting where staff are present 
(e.g begins when staff enter 
bedroom or in bath). 
Intentionally expose genitals, 
female breasts or buttocks to 
another person (appears to 
be a deliberate premeditated 
behaviour). 
Lifting skirts, pinching or 
touching buttocks, sitting on 
other’s knee. 
4 Explicit accounts of sexual intent, 
rquests or activity e.g. ‘show me 
your knickers’, ‘I want to shag you’. 
Masturbates without genitals 
being exposed in a public setting, 
including ward shared areas (e.g 
dining room). 
Masturbates with genitals 
being clearly exposed in a 
public setting, including ward 
shared areas. 
Touching others groin, female 
breasts, or rubbing own 
genitals or female’s breast 
against another person. 
 
3. Antecedents 
 Set One: Contributing Factors (Code 1-3)  Set Two: Observed directly before  (Coded 11-25) 
1 Structured activity. 11 Given direct verbal prompt to comply with instruction. 
2 Noisy environment. 12 Given verbal guidance/advice to assist completion of task/activity. 
3 Had epileptic fit in last 24 hours. 13 Given verbal/visual feedback about performance e.g token feedback. 
4 In dining room. 14 Direct response to other clients verbal behaviour. 
  15 Request specifically denied by other person. 
  16 Any other verbal interaction. 
  17 Physical guidance/facilitation including TA. 
  18 Direct response to other clients physically aggression (directed at them). 
  19 Direct response to other clients physically aggression (not directed at them). 
  20 During restraint/whilst being assisted to seclusion. 
  21 Given item e.g food. 
  22 Purposeful behaviour is TOOTS by person to whom it is directed at. 
  23 Obviously agitated or distressed. 
  24 No obvious antecedent. 
  25 Other (Please specify) 
 
4. Interventions 
A B C D E F G 
Aggression 
ignored.  TOOTS 
Talking to patient 
including prompts 
Closer 
observation. 
Holding patient 
(MOVA). 
PRN medication 
given by mouth. 
PRN medication given 
by injection. 
Isolation (no 
seclusion). 
H I J K L M N 
Seclusion Use of other 
restraints. 
Injury requires 
immediate 
medical 
treatment. 
Injury requires 
immediate medical 
treatment for 
other. 
Special 
programme. 
Physical distraction 
(leading the patient 
away). 
Other. 
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Appendix 2.5 Summary of Means and Standard Deviations (SDs) 
Microsoft Health 
AvHR AvHRDiff AvHRDiff Mean PeakHR PeakHRDiff PeakHRDiff Mean Physiological 
Participant N Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
1 Yes 16 80.75 6.20 -0.79 4.18 1.77 6.08 101.75 19.16 -0.21 9.51 7.39 18.95 
 No 973 78.99 7.08 -0.10 7.24 -0.03 7.07 94.36 14.93 -0.67 16.58 -0.13 14.84 
2 Yes 24 77.29 4.21 1.71 4.96 2.08 4.25 90.42 10.65 2.81 9.57 -6.18 14.15 
 No 757 74.96 7.19 -0.33 6.45 -0.17 7.66 88.00 12.11 -0.59 13.54 -6.10 16.10 
3 Yes 5 74.20 4.45 1.50 4.97 -1.04 4.45 85.60 4.67 -2.75 3.90 -7.01 4.67 
 No 619 75.18 6.86 -0.13 5.91 0.25 6.85 92.78 13.70 -0.37 15.2 0.15 13.70 
4 Yes 38 77.95 4.58 -0.11 4.4 4.14 4.50 89.45 8.48 -3.84 17.3 3.83 8.43 
 No 899 73.68 6.62 0.01 4.55 -0.09 6.58 85.54 10.93 0.11 11.86 -0.06 10.92 
5 Yesa 1 72.00 0.00 -9.00 0.00 1.97 0.00 83.00 0.00 -14.00 0.00 -5.09 0.00 
 No 364 71.13 7.78 -0.22 5.18 -0.20 7.67 88.29 12.56 -0.34 14.53 -0.23 12.54 
    
 MinHR MinHRDiff HrBefore 
MinHRDiff 
Mean StepCount 
StepCountDiffHr
Before 
StepCountDiff 
Mean 
Participant N Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
1 Yes 16 67.00 5.51 0.50 5.14 0.68 5.55 396.63 322.38 -67.29 372.43 33.91 321.67 
 No 973 66.30 6.33 -0.01 7.97 -0.01 6.32 364.36 433.44 -5.23 473.12 -0.56 432.54 
2 Yes 24 65.96 4.44 2.00 7.86 1.84 4.41 276.25 255.91 23.33 338.00 62.98 269.38 
 No 575 63.99 7.03 -0.10 8.17 -0.23 7.77 205.16 239.59 -0.2 252.46 -2.00 237.74 
3 Yes 5 65.80 1.72 2.75 2.49 1.91 1.72 342.40 240.72 125 422.70 -6.39 240.72 
 No 619 63.55 5.97 -0.05 7.51 0.19 5.95 417.54 533.78 -5.29 605.00 1.43 527.98 
4 Yes 38 69.29 4.29 0.61 5.71 3.33 4.19 198.58 233.76 -99.32 333.01 34.08 234.97 
 No 899 65.87 6.60 0.09 7.33 -0.06 6.57 162.77 297.38 4.66 358.25 -1.25 297.16 
5 Yesa 1 64.00 0.00 -4.00 0.00 4.20 0.00 494.00 0.00 378 0.00 -159.01 0.00 
 No 364 60.88 7.53 -0.12 5.47 -0.18 7.43 769.57 905.06 -20.05 998.3 -1.36 899.68 
N = total number of aggressive episodes captured, aValue derived from one aggressive episode, bNo aggressive episodes for collected data  
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Sleep   Duration   DurationDiff DurationDiffMean Awake   
Participant N Mean SD Mean SD Mean SD Mean SD 
1 Yes 11 28778.73 6858.88 1569.50 10.251.27 2994.55 6716.47 2333.73 916.83 
 No 23 25572.78 8509.12 7146.13 12206.58 -163.87 8548.02 2571.74 1417.57 
2 Yes 15 30619.00 12770.16 -2095.25 18884.10 2137.77 11604.45 10765.27 13559.44 
 No 22 26276.23 13395.78 -3955.90 17372.13 -1457.57 13856.34 6040.36 6179.17 
3 Yes 2 26343.50 5436.50 -2726.00 5212.00 650.43 5436.50 3036.50 793.50 
 No 20 25369.30 3429.63 1320.20 4414.69 -65.04 3419.88 3244.65 1430.87 
4 Yes 16 28931.81 10553.42 -6783.88 11314.57 593.36 10373.87 9040.13 2258.22 
 No 14 29218.14 11137.48 5847.67 7403.74 -678.13 10427.28 7845.36 3596.63 
5 Yesb 0         
  No 35 22648.76 7548.72 -367.60 9898.46 0.00 7548.72 5319.35 2460.68 
    
 AwakeDiff AwakeDiffMean LightSleep LightSleepDiff 
Participant N Mean SD Mean SD Mean SD Mean SD 
1 Yes 11 419.17 1473.59 -48.28 855.88 12102.27 3135.69 1061.83 6167.10 
 No 23 771.25 2020.40 202.60 1392.36 10487.3 4339.51 1851.88 6239.47 
2 Yes 15 -624.75 6316.12 1935.52 10915.63 7579.53 3926.36 -1191.00 9718.79 
 No 22 -1791.30 8273.45 -1319.67 7167.93 7477.59 4772.79 -926.10 5092.76 
3 Yes 2 -1107.50 389.50 284.00 793.50 13751.50 2652.50 -959.00 5689.00 
 No 20 173.20 1420.83 -28.40 1269.39 13902.90 2596.97 590.80 3762.57 
4 Yes 16 -293.00 4084.64 412.11 2183.57 17530.44 8476.47 -5948.38 8955.38 
 No 14 1828.67 2935.08 -470.99 3592.76 18844.86 8823.05 4392.50 3777.42 
5 Yesb 0         
  No 35 62.90 3157.42 0.00 2460.68 12555.47 4958.75 -26.00 6307.33 
 
continued 
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 Sleep 
  LightSleepDiffMean WakeUpsDiff WakeUps WakeUpsDiffMean 
Participant N Mean SD Mean SD Mean SD Mean SD 
1 Yes 11 1574.59 2727.64 -0.33 1.80 3.09 0.90 -0.27 0.86 
 No 23 -6.28 4424.61 1.00 3.67 3.78 2.23 0.43 2.20 
2 Yes 15 113.73 3946.22 1.25 2.28 3.73 2.64 0.61 2.52 
 No 22 -77.54 4746.63 -0.80 3.22 2.5 2.35 -0.42 2.34 
3 Yes 2 142.57 2652.5 -3.00 1.00 3.5 0.50 -1.29 0.50 
 No 20 -14.26 2567.67 0.40 1.56 5.8 2.23 0.13 2.00 
4 Yes 16 -38156.82 80814.41 -5.25 7.08 11.06 5.3 0.83 5.26 
 No 14 -87599.35 100598.26 2.33 2.98 9.64 4.55 -0.95 4.41 
5 Yesb 0         
  No 35 0.00 4958.75 -0.20 5.34 7.65 3.56 0.00 3.56 
   SleepEffDiff SleepEff   SleepEffDiffMean   
Participant N Mean SD Mean SD Mean SD   
1 Yes 11 -1.67 2.21 93.00 3.07 3.40 3.54   
 No 23 -0.38 5.65 91.74 4.76 2.20 5.14   
2 Yes 15 -9.25 7.15 77.73 21.72 -5.45 18.11   
 No 22 5.80 14.30 89.00 10.68 3.72 12.52   
3 Yes 2 5.00 2.00 92.50 2.50 0.43 2.50   
 No 20 -0.60 4.74 89.65 4.94 -0.04 4.02   
4 Yes 16 -6.00 11.83 70.19 12.32 -1.23 11.52   
 No 14 -2.83 6.91 75.79 12.58 1.40 11.16   
5 Yesb 0         
  No 35 -1.00 4.54 77.00 9.92 0.00 9.92   
N = total number of aggressive episodes captured, aValue derived from one aggressive episode, bNo aggressive episodes for 
collected data 
 
continued 
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TEAMED Patient       SkinResist-
anceSD 
SkinResist-
anceTrend Physiological HRSD  HRTrend HRPeaks HRVSD HRVTrend HRVPeaks 
Participant N Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
1 Yes 4 1.80 2.06 3.00 0.00 0.44 0.65 2.31 1.08 4.88 0.99 6.78 4.85 2.93 4.34 4.40 1.59 
 No 518 2.01 3.61 3.10 0.30 0.32 0.57 2.44 1.64 5.24 1.40 8.48 4.32 2.80 6.65 5.72 2.71 
2 Yes 5 3.83 1.69 -c -c 0.40 0.49 2.48 0.17 4.50 0.87 5.20 4.17 2.47 0.01 5.75 1.79 
 No 130 1.82 2.21 3.16 0.46 0.18 0.42 2.53 1.60 5.40 1.43 7.43 4.99 2.25 3.80 6.04 3.46 
3 Yesb 0                 
 No 92 2.76 4.83 3.53 0.82 0.35 0.62 2.44 1.80 4.83 1.34 7.08 4.60 2.93 3.75 6.07 5.32 
4 Yes 6 1.56 1.22 3.00 0.00 0.17 0.37 2.79 1.23 6.00 0.58 7.00 1.15 2.57 2.32 5.50 2.29 
 No 258 2.62 3.57 3.00 0.00 0.10 0.32 2.48 1.73 5.43 1.35 9.34 4.31 3.30 5.13 5.42 2.25 
5 Yesb 0                 
 No 20 3.23 1.97 3.00 0.00 0.05 0.22 0.58 1.30 4.56 1.42 2.05 1.83 -0.39 1.43 3.80 1.17 
 
 
SkinResistanc
eTrough 
SkinTemp 
SD 
SkinTemp 
Trend 
SkinTemp 
Peaks 
StepCountS
D 
StepCount 
Trend 
StepCount 
Peaks 
  
Participant N Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD   
1 Yes 4 0.56 0.65 1.74 1.56 8.86 2.42 1.11 0.30 4.74 4.73 4.00 0.00 3.22 2.82   
 No 518 0.52 0.88 2.33 4.09 11.14 6.80 0.63 0.73 2.48 3.54 3.13 0.33 2.57 2.88   
2 Yes 5 0.20 0.40 0.78 2.35 6.75 1.30 0.20 0.40 2.20 0.49 -c -c 2.80 1.83   
 No 130 0.47 0.65 1.43 4.83 9.76 5.87 0.56 0.64 3.23 4.09 3.13 0.48 2.76 2.85   
3 Yesb 0                 
 No 92 0.47 0.91 2.19 3.04 14.45 8.61 0.60 0.64 2.81 4.73 3.00 0.00 1.71 2.21   
4 Yes 6 0.00 0.00 1.47 1.30 11.83 2.79 0.67 0.75 2.11 2.82   2.00 1.91   
 No 258 0.28 0.63 2.61 3.91 11.22 5.42 0.54 0.59 2.66 4.67 3.30 0.46 1.56 2.12   
5 Yesb 0                 
 No 20 1.45 1.43 2.29 1.71 6.10 2.70 0.50 0.67 17.61 22.25 3.00 0.00 1.58 2.16   
N = total number of aggressive episodes captured, aValue derived from one aggressive episode, bNo aggressive episodes for collected data  cNot 
enough values for calculation of feature 
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Appendix 2.6 Algorithm Search Results 
 
Note:  Unless otherwise stated, the Cost-Sensitive Classification (cost) is placed on ‘Yes’ 
Only results of Validation set are presented for algorithms with SMOTE 
It was not possible to use SMOTE for TEAMED Application data due to the small 
number of aggressive episodes captured by the data 
 
Participant 1 
 
Microsoft Application 
Physiological 
 
1. Cost-Sensitive Classification with Cross-Validation 
Yes = 9, No = 585 
 
J48 
  
No 
  
Yes 
  
Cost MinNumObj N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
65 60 435 0.99 0.74 4 0.03 0.44 
65 40 463 0.99 0.79 4 0.03 0.44 
65 20 523 0.98 0.89 0 0.00 0.00 
55 80 457 0.99 0.78 4 0.03 0.44 
55 60 473 0.99 0.81 4 0.03 0.44 
55 40 477 0.99 0.82 3 0.03 0.33 
55 20 521 0.99 0.89 1 0.02 0.11 
45 80 457 0.99 0.78 4 0.03 0.44 
45 60 488 0.99 0.83 4 0.04 0.11 
45 40 475 0.99 0.81 3 0.03 0.33 
45 20 532 0.99 0.91 1 0.02 0.11 
35 80 458 0.99 0.78 4 0.03 0.44 
35 60 488 0.99 0.83 4 0.04 0.44 
35 40 482 0.98 0.82 1 0.01 0.11 
35 20 529 0.99 0.90 1 0.02 0.11 
25 40 539 0.98 0.92 0 0.00 0.00 
25 20 548 0.98 0.94 0 0.00 0.00 
25 10 541 0.98 0.93 0 0.00 0.00 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
85 333 0.98 0.57 3 0.01 0.33 
75 357 0.98 0.61 2 0.01 0.22 
65 392 0.98 0.67 1 0.01 0.11 
55 439 0.98 0.75 0 0.00 0.00 
45 476 0.98 0.81 0 0.00 0.00 
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Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
65.5 13 487 0.99 0.83 3 0.03 0.33 
65.5 11 403 0.99 0.69 5 0.31 0.03 
55.5 17 482 0.99 0.82 3 0.03 0.33 
55.5 15 484 0.99 0.83 3 0.03 0.33 
55.5 13 525 0.99 0.90 2 0.03 0.22 
55.5 11 491 0.99 0.84 2 0.02 0.22 
45.5 13 498 0.98 0.85 0 0.00 0.00 
45.5 11 514 0.99 0.88 1 0.01 0.11 
 
2. SMOTE with Percentage Split 
Training Set – Yes = 4, No = 412 
Validation Set – Yes = 5, No = 173 
 
J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNum 
Obj 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
14300 60 146 0.99 0.84 3 0.10 0.60 
14300 40 144 0.99 0.83 3 0.09 0.60 
14300 20 165 0.98 0.95 2 0.20 0.40 
12300 60 145 0.98 0.84 2 0.07 0.40 
12300 40 152 0.99 0.88 3 0.13 0.60 
12300 20 166 0.98 0.96 2 0.22 0.40 
10300 60 146 0.98 0.84 2 0.07 0.40 
10300 40 147 0.99 0.85 3 0.10 0.60 
10300 20 170 0.98 0.98 1 0.25 0.20 
8300 60 158 0.98 0.91 2 0.12 0.40 
8300 40 155 0.99 0.90 3 0.14 0.60 
8300 20 170 0.98 0.98 1 0.25 0.20 
6300 40 167 0.97 0.97 0 0.00 0.00 
6300 20 171 0.97 0.09 0 0.00 0.00 
 
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
16300 94 0.96 0.54 1 0.01 0.20 
14300 97 0.96 0.56 1 0.01 0.20 
12300 108 0.96 0.62 0 0.00 0.00 
10300 120 0.96 0.69 0 0.00 0.00 
8300 136 0.99 0.79 0 0.00 0.00 
6300 154 0.97 0.89 0 0.00 0.00 
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Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
12300 19 168 0.98 0.97 1 0.17 0.20 
12300 17 166 0.97 0.96 1 0.12 2.20 
12300 15 166 0.98 0.96 1 0.13 0.20 
12300 13 166 0.98 0.96 1 0.13 0.20 
12300 11 163 0.98 0.94 1 0.09 0.20 
10300 19 166 0.98 0.96 1 0.13 0.20 
10300 17 166 0.98 0.96 1 0.13 0.20 
10300 15 163 0.98 0.94 1 0.09 0.20 
10300 13 163 0.98 0.94 1 0.09 0.20 
10300 11 160 0.98 0.93 1 0.07 0.10 
 
Sleep 
 
1. Cost-Sensitive Classification with Cross-Validation 
Yes = 7, No = 15 
 
J48 
  
No 
  
Yes 
  
Cost MinNum 
Obj 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
4 6 0 0.00 0.00 6 0.27 0.86 
4 4 2 0.67 0.13 6 0.32 0.86 
4 2 1 0.50 0.07 6 0.30 0.86 
3 6 2 0.33 0.13 3 0.87 0.19 
3 4 3 0.60 0.20 5 0.29 0.71 
3 2 0 0.00 0.00 6 0.29 0.86 
2 6 5 0.42 0.33 0 0.00 0.00 
2 4 9 0.56 0.60 0 0.00 0.00 
2 2 11 0.73 0.73 3 0.27 0.43 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
8 10 0.71 0.67 3 0.38 0.43 
7 10 0.71 0.67 3 0.38 0.43 
6 10 0.71 0.67 3 0.38 0.43 
5 10 0.71 0.67 3 0.38 0.43 
4 10 0.71 0.67 3 0.38 0.43 
3 9 0.64 0.60 2 0.25 0.29 
2 10 0.67 0.67 2 0.29 0.29 
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Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
4 20 7 0.58 0.47 2 0.20 0.29 
4 18 6 0.55 0.40 2 0.18 0.29 
4 16 8 0.62 0.53 2 0.22 0.29 
4 14 6 0.55 0.40 2 0.18 0.29 
3 20 7 0.58 0.47 2 0.20 0.29 
3 18 6 0.55 0.40 2 0.18 0.29 
3 16 7 0.58 0.47 2 0.20 0.29 
3 14 6 0.55 0.40 2 0.18 0.29 
2 20 7 0.58 0.47 2 0.20 0.29 
2 18 7 0.58 0.47 2 0.20 0.29 
2 16 7 0.58 0.47 2 0.20 0.29 
2 14 7 0.58 0.47 2 0.20 0.29 
 
2. SMOTE with Percentage Split 
Training Set – Yes = 3, No = 10 
Validation Set – Yes – 4, No = 5 
 
J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNum 
Obj 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
300 4 0 0.00 0.00 3 0.46 0.75 
300 2 5 0.56 1.00 0 0.00 0.00 
200 6 5 0.56 1.00 0 0.00 0.00 
200 4 5 0.63 1.00 1 1.00 0.25 
200 2 5 0.63 1.00 1 1.00 0.25 
100 6 5 0.56 1.00 0 0.00 0.00 
100 4 5 0.63 1.00 1 1.00 0.25 
100 2 4 0.67 0.80 2 0.67 0.50 
50 6 5 0.56 1.00 0 0.00 0.00 
50 4 5 0.63 1.00 1 1.00 0.25 
50 2 5 0.56 1.00 0 0.00 0.00 
 
 120  
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
600 3 0.75 0.60 3 0.60 0.75 
500 4 1.00 0.80 4 0.80 1.00 
400 4 1.00 0.80 4 0.80 1.00 
300 3 0.75 0.60 3 0.60 0.75 
200 2 0.50 0.40 2 0.50 0.40 
100 4 0.67 0.80 2 0.67 0.50 
50 4 0.67 0.80 2 0.67 0.50 
0 4 0.67 0.80 2 0.67 0.50 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
500 20 4 0.57 0.80 1 0.50 0.25 
500 18 4 0.57 0.80 1 0.50 0.25 
500 16 4 0.57 0.80 1 0.50 0.25 
500 14 4 0.57 0.80 1 0.50 0.25 
400 18 5 0.63 1.00 1 1.00 0.25 
400 16 5 0.63 1.00 1 1.00 0.25 
400 14 5 0.63 1.00 1 1.00 0.25 
300 18 5 0.63 1.00 1 1.00 0.25 
300 16 5 0.63 1.00 1 1.00 0.25 
300 14 5 0.63 1.00 1 1.00 0.25 
200 18 5 0.63 1.00 1 1.00 0.25 
200 16 5 0.63 1.00 1 1.00 0.25 
200 14 5 0.63 1.00 1 1.00 0.25 
100 22 5 0.71 1.00 2 1.00 0.50 
100 20 5 0.71 1.00 2 1.00 0.50 
100 18 4 0.67 0.80 2 0.67 0.50 
100 16 4 0.67 0.80 2 0.67 0.50 
100 14 5 0.63 1.00 1 1.00 0.25 
 
TEAMED Application 
 
Physiological 
 
1. Cost-Sensitive Classification with Cross-Validation 
Yes = 4, No = 251 
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J48 
  
No 
  
Yes 
  
Cost MinNum 
Obj 
N Correct Precision Recall N 
Correct 
Precision Recall 
140 40 166 0.98 0.66 0 0.00 0.00 
140 30 150 0.98 0.60 1 0.01 0.25 
140 20 212 0.98 0.85 0 0.00 0.00 
120 40 158 0.99 0.63 3 0.03 0.75 
120 30 156 0.98 0.62 0 0.00 0.00 
120 20 212 0.98 0.86 0 0.00 0.00 
100 50 166 0.98 0.66 0 0.00 0.00 
100 40 125 0.98 0.50 0 0.00 0.00 
100 30 209 0.98 0.83 0 0.00 0.00 
100 20 212 0.98 0.85 0 0.00 0.00 
80 60 164 0.99 0.65 0 0.00 0.00 
80 50 186 0.98 0.74 0 0.00 0.00 
80 40 160 0.98 0.64 0 0.00 0.00 
80 30 210 0.98 0.84 0 0.00 0.00 
80 20 213 0.98 0.85 0 0.00 0.00 
60 70 182 0.98 0.73 0 0.00 0.00 
60 60 178 0.98 0.71 1 0.01 0.25 
60 50 151 0.97 0.60 0 0.00 0.00 
60 40 211 0.99 0.84 1 0.02 0.25 
60 30 209 0.98 0.83 0 0.00 0.00 
60 20 219 0.98 0.87 0 0.00 0.00 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
200 237 0.98 0.94 0 0.00 0.00 
180 238 0.98 0.95 0 0.00 0.00 
160 237 0.98 0.94 0 0.00 0.00 
140 235 0.98 0.96 0 0.00 0.00 
120 234 0.98 0.93 0 0.00 0.00 
100 235 0.98 0.94 0 0.00 0.00 
80 236 0.98 0.94 0 0.00 0.00 
60 238 0.98 0.95 0 0.00 0.00 
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Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
130 22 140 0.99 0.56 2 0.02 0.50 
130 20 206 0.99 0.82 1 0.02 0.25 
130 18 209 0.99 0.83 1 0.02 0.25 
130 14 235 0.98 0.94 0 0.00 0.00 
120 24 140 0.99 0.56 2 0.02 0.50 
120 22 176 0.99 0.70 2 0.03 0.50 
120 20 210 0.99 0.84 1 0.02 0.25 
120 18 233 0.98 0.93 0 0.00 0.00 
120 16 235 0.98 0.94 0 0.00 0.00 
120 14 233 0.98 928 0 0.00 0.00 
100 22 210 0.99 0.84 0 0.00 0.00 
100 20 234 0.98 0.93 0 0.00 0.00 
100 18 236 0.98 0.94 0 0.00 0.00 
100 16 235 0.98 0.94 0 0.00 0.00 
100 14 235 0.98 0.94 0 0.00 0.00 
80 22 236 0.98 0.94 0 0.00 0.00 
80 18 234 0.98 0.93 0 0.00 0.00 
80 14 237 0.98 0.94 0 0.00 0.00 
60 22 234 0.98 0.95 0 0.00 0.00 
60 18 235 0.98 0.94 0 0.00 0.00 
60 14 239 0.98 0.95 0 0.00 0.00 
 
 
Participant 2 
 
Microsoft Application 
Physiological 
 
1. Weight with Cross Validation 
Yes = 16, No = 581 
 
J48 
  
No 
  
Yes 
  
Cost MinNumObj N Correct Precision Recall N Correct Precision Recall 
55 80 295 0.98 0.51 10 0.03 0.63 
55 60 308 0.98 0.53 9 0.03 0.56 
55 40 400 0.98 0.31 7 0.04 0.44 
45 60 400 0.97 0.69 4 0.02 0.25 
45 40 416 0.98 0.72 8 0.05 0.50 
45 20 430 0.98 0.74 5 0.03 0.31 
35 80 389 0.97 0.67 4 0.02 0.25 
35 60 436 0.97 0.75 4 0.03 0.25 
35 40 450 0.97 0.78 4 0.03 0.25 
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Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
45 362 0.98 0.62 8 0.04 0.50 
35 388 0.98 0.67 6 0.03 0.38 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
55 13 349 0.98 0.60 7 0.03 0.44 
55 11 371 0.97 0.64 4 0.02 0.25 
45 13 401 0.97 0.69 5 0.03 0.31 
45 11 449 0.98 0.77 6 0.04 0.38 
35 19 434 0.98 0.75 5 0.25 0.31 
35 17 449 0.98 0.77 6 0.04 0.38 
35 15 464 0.97 0.80 3 0.03 0.19 
35 13 462 0.97 0.80 3 0.03 0.19 
35 11 488 0.97 0.84 1 0.01 0.06 
 
2. SMOTE with Percentage Split 
Note: Only results of Validation set are presented 
 
Training Set – Yes = 10, No = 347 
Validation Set – Yes = 6, No = 234 
 
J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNumObj N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
4200 100 209 0.97 0.89 0 0.00 0.00 
4200 80 183 0.97 0.78 1 0.02 0.17 
4200 60 183 0.97 0.78 1 0.02 0.17 
4200 40 183 0.97 0.78 1 0.02 0.17 
4200 20 209 0.97 0.89 
   
4000 60 181 0.98 0.77 2 0.04 0.33 
4000 40 181 0.98 0.77 2 0.04 0.33 
4000 20 209 0.97 0.89 0 0.00 0.00 
3800 80 192 0.97 0.82 0 0.00 0.00 
3800 60 183 0.97 0.78 1 0.02 0.17 
3800 40 183 0.98 0.78 1 0.02 0.17 
3800 20 209 0.97 0.89 0 0.00 0.00 
3600 80 198 0.97 0.82 0 0.00 0.00 
3600 60 181 0.98 0.77 2 0.04 0.33 
3600 40 183 0.97 0.78 1 0.02 0.17 
3600 20 209 0.97 0.89 0 0.00 0.00 
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3400 80 190 0.97 0.81 1 0.02 0.17 
3400 60 181 0.98 0.77 2 0.23 0.04 
3400 40 194 0.98 0.83 1 0.02 0.17 
3400 20 208 0.97 0.89 0 0.00 0.00 
3200 80 202 0.98 0.86 1 0.03 0.17 
3200 60 188 0.98 0.80 2 0.20 0.33 
3200 40 201 0.98 0.87 1 0.03 0.17 
3200 20 198 0.98 0.85 1 0.03 0.17 
3000 60 192 0.98 0.82 1 0.02 0.17 
3000 40 202 0.98 0.86 1 0.03 0.17 
3000 20 199 0.98 0.85 1 0.03 0.17 
 
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
4200 180 0.97 0.77 1 0.02 0.17 
4000 181 0.97 0.77 1 0.02 0.17 
3800 182 0.97 0.78 1 0.02 0.17 
3600 183 0.97 0.78 1 0.02 0.17 
3400 187 0.97 0.80 1 0.02 0.17 
3200 189 0.97 0.81 1 0.02 0.17 
3000 190 0.97 0.81 1 0.02 0.17 
2000 203 0.98 0.87 1 0.03 0.17 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
3600 15 219 0.97 0.94 0 0.00 0.00 
3600 13 216 0.98 0.92 1 0.05 0.95 
3600 11 220 0.97 0.94 0 0.00 0.00 
3400 13 217 0.97 0.93 0 0.00 0.00 
3400 11 217 0.98 0.93 1 0.06 0.17 
3200 17 223 0.97 0.95 0 0.00 0.00 
3200 15 219 0.98 0.94 1 0.06 0.17 
3200 13 221 0.98 0.94 1 0.07 0.17 
3200 11 223 0.97 0.95 0 0.00 0.00 
 
Sleep 
 
1. Cost-Sensitive Classification with Cross-Validation 
Yes = 12, No = 20 
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J48 
  
No 
  
Yes 
  
Cost MinNum 
Obj 
N Correct Precision Recall N Correct Precision Recall 
2 4 2 0.40 1.00 12 1.00 0.10 
2 3 6 0.75 0.30 10 0.42 0.83 
2 2 6 0.60 0.30 8 0.36 0.67 
1.5 4 14 0.58 0.70 2 0.25 0.17 
1.5 3 16 0.64 0.80 3 0.43 0.25 
1.5 2 17 0.59 0.85 0 0.00 0.00 
1 4 19 0.61 0.95 0 0.00 0.00 
1 3 18 0.62 0.90 1 0.33 0.08 
1 2 20 0.63 0.10 0 0.00 0.00 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
7 6 0.55 0.30 7 0.33 0.58 
6 6 0.55 0.30 7 0.33 0.58 
5 7 0.58 0.35 7 0.35 0.58 
4 7 0.54 0.35 6 0.32 0.50 
3 7 0.50 0.35 5 0.28 0.42 
2 7 0.47 0.35 4 0.24 0.33 
1 8 0.53 0.40 5 0.29 0.42 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
4 18 7 0.47 0.35 4 0.24 0.33 
4 16 5 0.38 0.25 4 0.21 0.33 
4 14 7 0.47 0.35 4 0.24 0.33 
3 18 7 0.44 0.35 3 0.19 0.25 
3 16 8 0.47 0.40 3 0.20 0.25 
3 14 8 0.47 0.40 3 0.20 0.25 
2 18 7 0.44 0.35 3 0.19 0.25 
2 16 7 0.44 0.35 3 0.19 0.25 
2 14 7 0.44 0.35 3 0.19 0.25 
1 18 10 0.50 0.50 2 0.17 0.17 
1 16 9 0.47 0.45 2 0.15 0.17 
1 14 8 0.44 0.40 2 0.14 0.17 
 
 
2. SMOTE with Percentage Split 
 
Training Set – Yes = 7, No = 11 
Validation Set – Yes = 5, No = 9 
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J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNum
Obj 
N Correct Precision Recall N 
Correct 
Precision Recall 
200 8 3 0.43 0.33 1 0.14 0.20 
200 6 3 0.60 0.33 3 0.33 0.60 
200 4 2 0.67 0.22 4 0.67 0.22 
200 2 2 0.67 0.22 4 0.67 0.22 
100 8 3 0.43 0.33 1 0.14 0.20 
100 6 3 0.60 0.33 3 0.33 0.60 
100 4 2 0.67 0.22 4 0.36 0.80 
100 2 2 0.67 0.22 4 0.36 0.80 
50 8 2 0.40 0.22 2 0.22 0.40 
50 6 3 0.60 0.33 3 0.33 0.60 
50 4 6 0.60 0.67 1 0.25 0.20 
50 2 7 0.64 0.78 1 0.33 0.20 
 
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N 
Correct 
Precision Recall N Correct Precision Recall 
300 3 0.60 0.33 3 0.33 0.60 
200 3 0.60 0.33 3 0.33 0.60 
100 5 0.62 0.56 2 0.33 0.40 
50 5 0.62 0.56 2 0.33 0.40 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N Correct Precision Recall N 
Correct 
Precision Recall 
300 18 3 0.50 0.33 2 0.25 0.40 
300 16 3 0.50 0.33 2 0.25 0.40 
300 14 3 0.50 0.33 2 0.25 0.40 
200 18 5 0.83 0.56 4 0.50 0.80 
200 16 4 0.80 0.44 4 0.44 0.80 
200 14 4 0.80 0.44 4 0.44 0.80 
100 18 4 0.50 0.44 1 0.17 0.20 
100 16 4 0.50 0.44 1 0.17 0.20 
100 14 4 0.50 0.44 1 0.17 0.20 
50 18 4 0.67 0.44 3 0.38 0.60 
50 16 5 0.63 0.56 2 0.33 0.40 
50 14 4 0.67 0.44 3 0.38 0.60 
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TEAMED Application 
 
Physiological 
 
1. Cost-Sensitive Classification with Cross-Validation 
Yes = 3, No = 80 
 
J48 
  
No 
  
Yes 
  
Cost MinNum 
Obj 
N 
Correct 
Precision Recall N Correct Precision Recall 
125 10 6 0.86 0.08 2 0.03 0.67 
125 8 15 0.88 19 1 0.02 0.33 
125 6 31 0.94 0.39 1 0.02 0.33 
125 4 51 0.94 0.64 0 0.00 0.00 
125 2 58 0.95 0.73 0 0.00 0.00 
105 10 6 0.86 0.08 2 0.03 0.67 
105 8 14 0.88 0.18 1 0.02 0.33 
105 6 42 0.93 0.53 0 0.00 0.00 
105 4 60 0.95 0.75 0 0.00 0.00 
105 2 60 0.95 0.75 0 0.00 0.00 
105 10 14 0.88 0.18 1 0.02 0.33 
105 8 40 0.95 0.50 1 0.02 0.33 
85 6 43 0.95 0.38 0 0.00 0.00 
85 4 55 0.95 0.69 0 0.00 0.00 
85 2 64 0.96 0.80 0 0.00 0.00 
85 10 31 0.94 0.39 0 0.00 0.00 
85 8 43 0.94 0.54 0 0.00 0.00 
65 6 63 0.96 0.79 0 0.00 0.00 
65 2 65 0.96 0.81 0 0.00 0.00 
45 10 57 0.95 0.71 0 0.00 0.00 
45 8 57 0.95 0.71 0 0.00 0.00 
45 6 56 0.95 0.70 0 0.00 0.00 
45 4 59 0.95 0.74 0 0.00 0.00 
45 2 68 0.96 0.9 0 0.00 0.00 
25 12 55 0.96 0.69 0 0.00 0.00 
25 8 54 0.95 0.68 0 0.00 0.00 
25 6 59 0.95 0.74 0 0.00 0.00 
25 4 66 0.96 0.83 0 0.00 0.00 
25 2 68 0.96 0.85 0 0.00 0.00 
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Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
125 64 0.97 0.80 1 0.06 0.33 
105 66 0.97 0.83 1 0.07 0.33 
85 64 0.97 0.06 1 0.059 0.33 
65 65 0.97 0.81 1 0.188 0.06 
45 64 0.97 0.06 1 0.059 0.33 
25 64 0.96 0.80 0 0.00 0.00 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
125 20 65 0.96 0.81 0 0 0 
125 18 65 0.96 0.81 0 0 0 
125 16 65 0.96 0.81 0 0 0 
125 14 63 0.96 0.79 0 0 0 
105 20 65 0.96 0.81 0 0 0 
105 18 65 0.96 0.81 0 0 0 
105 16 65 0.96 0.81 0 0 0 
105 14 63 0.96 0.79 0 0 0 
85 20 65 0.96 0.81 0 0 0 
85 18 65 0.96 0.81 0 0 0 
85 16 65 0.96 0.81 0 0 0 
85 14 63 0.96 0.79 0 0 0 
65 20 63 0.96 0.79 0 0 0 
65 18 65 0.96 0.81 0 0 0 
65 16 63 0.96 0.79 0 0 0 
65 14 63 0.96 0.79 0 0 0 
45 18 63 0.96 0.79 0 0 0 
45 16 64 0.96 0.80 0 0 0 
45 14 63 0.96 0.79 0 0 0 
25 16 61 0.95 0.76 0 0 0 
25 14 65 0.96 0.81 0 0 0 
 
 
Participant 4 
 
Microsoft Application 
Physiological 
 
1. Cost-Sensitive Classification with Cross Validation 
Yes = 20, No = 495 
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J48 
  
No 
  
Yes 
  
Cost MinNumOb
j 
N 
Correct 
Precision Recall N Correct Precision Recall 
35 70 283 0.983 0.572 15 0.066 0.75 
35 50 336 0.971 0.679 10 0.059 0.5 
25 90 300 0.971 0.606 11 0.053 0.55 
25 70 314 0.984 0.634 15 0.077 0.75 
25 50 357 0.967 0.721 8 0.055 0.4 
15 90 364 0.96 0.73 5 0.037 0.25 
15 70 378 0.967 0.764 7 0.056 0.35 
15 50 391 0.958 0.79 3 0.028 0.15 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N 
Correct 
Precision Recall N Correct Precision Recall 
35 279 0.982 0.564 15 0.065 0.75 
25 334 0.979 0.675 13 0.075 0.65 
20 374 0.974 0.756 10 0.076 0.5 
15 415 0.972 0.838 8 0.091 0.4 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
35 17 325 0.973 0.657 11 0.061 0.55 
35 15 325 0.976 0.657 12 0.066 0.6 
35 13 323 0.973 0.653 11 0.06 0.55 
35 11 307 0.978 0.62 13 0.065 0.65 
25 15 373 0.969 0.754 8 0.062 0.4 
25 13 389 0.97 0.786 8 0.07 0.4 
25 11 377 0.969 0.762 8 0.063 0.4 
 
2.  SMOTE with Percentage Split 
Training Set – Yes = 13, No = 295 
Validation Set – Yes = 7, No = 200 
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J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNum 
Obj 
N Correct Precision Recall N 
Correct 
Precision Recall 
2400 90 131 0.97 0.66 3 0.04 0.43 
2400 70 110 0.99 0.55 6 0.06 0.86 
2400 50 108 0.99 0.54 6 0.06 0.86 
2200 70 110 0.99 0.55 6 0.06 0.86 
2200 50 131 0.99 0.66 5 0.07 0.71 
2000 70 110 0.99 0.55 6 0.06 0.86 
2000 50 160 0.96 0.80 1 0.02 0.14 
 
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N Correct Precision Recall N Correct Precision Recall 
2400 98 0.99 0.49 6 0.06 0.86 
2200 96 1.00 0.48 7 0.06 1.00 
2000 105 0.99 0.53 6 0.06 0.86 
1800 117 0.99 0.07 6 0.07 0.86 
1400 131 0.99 0.66 6 0.08 0.86 
1200 144 0.99 0.72 5 0.08 0.71 
1000 161 0.97 0.81 2 0.05 0.29 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
2600 17 164 0.97 0.82 1 0.03 0.14 
2600 15 163 0.96 0.82 1 0.03 0.14 
2600 13 154 0.96 0.77 1 0.02 0.14 
2600 11 144 0.96 0.72 1 0.02 0.14 
2400 15 117 0.98 0.59 5 0.06 0.71 
2400 13 123 0.96 0.62 2 0.03 0.29 
2400 11 119 0.96 0.60 2 0.02 0.29 
2200 13 140 0.96 0.70 1 0.02 0.14 
2200 11 150 0.96 0.75 1 0.02 0.14 
 
Sleep 
 
1. Cost-Sensitive Classification with Cross Validation 
Note: Cost-Sensitive Classification placed on ‘No’ values 
 
Yes = 13, No = 8 
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J48 
  
No 
  
Yes 
  
Cost MinNum
Obj 
N Correct Precision Recall N Correct Precision Recall 
1 6 0 0.00 0.00 10 0.56 0.77 
1 4 0 0.00 0.00 10 0.56 0.77 
1 2 0 0.00 0.00 10 0.56 0.77 
1.5 6 2 0.22 0.25 6 0.50 0.46 
1.5 4 1 0.17 0.13 8 0.53 0.62 
1.5 2 4 0.50 0.50 9 0.69 0.69 
2 6 6 0.33 0.75 1 0.33 0.08 
2 4 3 0.23 0.38 3 0.38 0.23 
2 2 5 0.42 0.63 6 0.67 0.46 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
1 1 0.11 0.13 5 0.42 0.39 
2 2 0.25 0.25 7 0.54 0.54 
3 2 0.22 0.25 6 0.50 0.46 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
1 18 1 0.17 0.13 8 0.53 0.62 
1 16 1 0.14 0.13 7 0.50 0.54 
1 14 0 0.00 0.00 6 0.43 0.46 
2 18 3 0.25 0.38 4 0.44 0.31 
2 16 3 0.25 0.38 4 0.44 0.31 
2 14 3 0.38 0.23 3 0.23 0.38 
 
 
2. SMOTE with Percentage Split 
Note: Oversampling placed on ‘No’ values as it is the minority class 
Training set – Yes = 8, No = 4 
Validation set – Yes = 8, No = 4 
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J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNumObj 
 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
100 6 0 0.00 0.00 4 0.50 0.80 
100 4 0 0.00 0.00 4 0.50 0.80 
100 2 0 0.00 0.00 4 0.50 0.80 
200 6 0 0.00 0.00 4 0.50 0.80 
200 4 0 0.00 0.00 4 0.50 0.80 
200 2 0 0.00 0.00 4 0.50 0.80 
300 6 0 0.00 0.00 4 0.50 0.80 
300 4 0 0.00 0.00 4 0.50 0.80 
300 2 0 0.00 0.00 4 0.50 0.80 
400 6 0 0.00 0.00 4 0.50 0.80 
400 4 0 0.00 0.00 4 0.50 0.80 
400 2 0 0.00 0.00 4 0.50 0.80 
 
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N Correct Precision Recall N Correct Precision Recall 
100 1 0.20 0.25 1 0.20 0.25 
200 1 0.20 0.25 1 0.20 0.25 
300 1 0.25 0.25 2 0.40 0.40 
400 0 0.00 0.00 2 0.33 0.40 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
0 18 1 0.20 0.25 1 0.20 0.25 
0 16 1 0.20 0.25 1 0.20 0.25 
0 14 1 0.20 0.25 1 0.20 0.25 
100 18 1 0.20 0.25 1 0.20 0.25 
100 16 1 0.20 0.25 1 0.20 0.25 
100 14 1 0.20 0.25 1 0.20 0.25 
200 18 1 0.20 0.25 1 0.20 0.25 
200 16 1 0.20 0.25 1 0.20 0.25 
200 14 1 0.20 0.25 1 0.20 0.25 
 
TEAMED Application 
 
Physiological  
 
1. Cost-Sensitive Classification with Cross-Validation 
Yes = 4, No = 178 
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J48 
  
No 
  
Yes 
  
Cost MinNumObj N Correct Precision Recall N Correct Precision Recall 
55 50 126 0.98 0.71 1 0.02 0.25 
55 40 113 0.99 0.64 3 0.37 0.75 
55 30 113 0.99 0.64 3 0.37 0.75 
55 20 113 0.99 0.64 3 0.37 0.75 
55 10 152 0.98 0.85 1 0.04 0.25 
45 60 131 0.97 0.74 0 0.00 0.00 
45 50 121 0.99 0.68 3 0.05 0.75 
45 40 113 0.99 0.64 3 0.04 0.75 
45 30 125 0.98 0.70 1 0.02 0.25 
45 20 128 0.98 0.72 1 0.02 0.25 
35 80 145 0.97 0.82 0 0.00 0.00 
35 70 134 0.99 0.75 2 0.04 0.50 
35 60 124 0.98 0.70 2 0.04 0.50 
35 50 113 0.99 0.64 3 0.04 0.75 
35 40 113 0.99 0.64 3 0.04 0.75 
35 30 125 0.98 0.70 1 0.02 0.25 
35 20 157 0.98 0.88 1 0.05 0.25 
35 10 158 0.98 0.89 1 0.05 0.25 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
135 144 0.97 0.81 0 0.00 0.00 
125 144 0.97 0.81 0 0.00 0.00 
115 145 0.97 0.82 0 0.00 0.00 
105 145 0.97 0.82 0 0.00 0.00 
95 145 0.97 0.82 0 0.00 0.00 
85 145 0.97 0.82 0 0.00 0.00 
75 146 0.97 0.82 0 0.00 0.00 
65 146 0.97 0.82 0 0.00 0.00 
55 147 0.97 0.83 0 0.00 0.00 
45 148 0.97 0.83 0 0.00 0.00 
35 152 0.97 0.85 0 0.00 0.00 
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Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
115 20 152 0.97 0.85 0 0.00 0.00 
115 18 135 0.97 0.76 0 0.00 0.00 
115 16 120 0.98 0.67 2 0.03 0.50 
115 14 145 0.98 0.82 1 0.03 0.25 
105 20 152 0.98 0.85 1 0.04 0.25 
105 18 137 0.99 0.77 2 0.05 0.50 
105 16 134 0.99 0.75 2 0.25 0.04 
105 14 153 0.98 0.86 0 0.00 0.00 
95 22 141 0.98 0.79 1 0.03 0.03 
95 20 154 0.98 0.87 1 0.04 0.25 
95 18 152 0.97 0.85 0 0.00 0.00 
95 16 156 0.96 0.88 0 0.00 0.00 
95 14 152 0.97 0.85 0 0.00 0.00 
85 20 141 0.98 0.86 0 0.00 0.00 
85 18 153 0.98 0.86 0 0.00 0.00 
85 16 153 0.98 0.86 0 0.00 0.00 
85 14 157 0.98 0.88 0 0.00 0.00 
75 22 153 0.98 0.86 0 0.00 0.00 
75 20 153 0.98 0.86 0 0.00 0.00 
75 18 154 0.96 0.87 0 0.00 0.00 
75 16 156 0.96 0.88 0 0.00 0.00 
75 14 156 0.96 0.88 0 0.00 0.00 
65 20 158 0.98 0.89 0 0.00 0.00 
65 18 159 0.98 0.89 0 0.00 0.00 
65 16 160 0.98 0.90 0 0.00 0.00 
65 14 158 0.96 0.89 0 0.00 0.00 
55 20 161 0.98 0.90 0 0.00 0.00 
55 18 161 0.98 0.90 0 0.00 0.00 
55 16 161 0.98 0.90 0 0.00 0.00 
55 14 162 0.98 0.91 0 0.00 0.00 
45 22 161 0.98 0.90 0 0.00 0.00 
45 20 163 0.98 0.92 0 0.00 0.00 
45 18 163 0.98 0.92 0 0.00 0.00 
45 16 166 0.98 0.93 0 0.00 0.00 
45 14 166 0.98 0.93 0 0.00 0.00 
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Participant 1-5 
 
Microsoft Application 
Physiological 
 
1. Cost-Sensitive Classification with Cross Validation 
Yes = 50, No = 2233 
 
J48 
  
No 
  
Yes 
  
Cost MinNumObj N Correct Precision Recall N Correct Precision Recall 
55 230 1325 0.99 0.59 34 0.04 0.68 
55 210 1409 0.99 0.63 29 0.03 0.58 
55 190 1510 0.99 0.68 28 0.04 0.56 
55 170 1527 0.99 0.68 27 0.04 0.54 
55 150 1503 0.98 0.67 22 0.03 0.44 
45 250 1431 0.99 0.64 28 0.03 0.56 
45 230 1489 0.99 0.67 29 0.04 0.58 
45 210 1526 0.99 0.68 27 0.04 0.54 
45 190 1567 0.98 0.70 25 0.04 0.50 
45 170 1604 0.98 0.72 24 0.04 0.48 
35 250 1675 0.98 0.76 14 0.02 0.28 
35 230 1650 0.98 0.74 24 0.04 0.48 
35 210 1713 0.99 0.77 24 0.04 0.48 
35 190 1662 0.98 0.74 23 0.04 0.46 
25 250 1745 0.98 0.78 12 0.02 0.24 
25 230 1789 0.98 0.80 13 0.03 0.26 
25 210 1805 0.98 0.81 18 0.04 0.36 
25 190 1848 0.98 0.83 15 0.04 0.30 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
55 1263 0.99 0.57 34 0.03 0.68 
45 1395 0.99 0.63 30 0.04 0.60 
35 1601 0.98 0.72 21 0.03 0.42 
25 1848 0.98 0.83 15 0.04 0.30 
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Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
55 17 1417 0.99 0.64 34 0.04 0.68 
55 15 1462 0.99 0.66 30 0.04 0.60 
55 13 1440 0.99 0.65 30 0.04 0.60 
55 11 1306 0.99 0.59 34 0.04 0.68 
45 21 1554 0.99 0.70 32 0.05 0.06 
45 19 1575 0.99 0.71 30 0.04 0.60 
45 17 1590 0.99 0.71 29 0.04 0.58 
45 15 1549 0.99 0.69 29 0.04 0.58 
45 13 1519 0.98 0.68 25 0.03 0.50 
45 11 1507 0.99 0.68 34 0.05 0.68 
35 21 1706 0.98 0.76 23 0.04 0.46 
35 19 1693 0.99 0.76 27 0.05 0.54 
35 17 1725 0.99 0.77 24 0.05 0.48 
35 15 1663 0.99 0.75 32 0.05 0.64 
35 13 1708 0.99 0.77 27 0.05 0.54 
35 11 1633 0.99 0.73 29 0.05 0.58 
25 19 1883 0.98 0.84 18 0.05 0.36 
25 15 1823 0.99 0.82 22 0.05 0.44 
25 11 1845 0.99 0.83 21 0.05 0.42 
 
2. SMOTE with Percentage Split 
 
Training Data – Yes = 28, No = 1507 
Validation Data – Yes = 22, No = 837 
 
J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNumO
bj 
N 
Correct 
Precision Recall N Correct Precision Recall 
5500 230 672 0.98 0.80 7 0.04 0.32 
5500 190 650 0.98 0.78 8 0.04 0.36 
5500 150 603 0.98 0.72 8 0.03 0.36 
5500 110 661 0.99 0.79 7 0.04 0.32 
5300 210 690 0.98 0.82 5 0.03 0.23 
5300 190 593 0.98 0.71 11 0.04 0.50 
5300 150 633 0.98 0.76 8 0.04 0.36 
5300 110 654 0.98 0.78 8 0.04 0.36 
5100 290 595 0.98 0.71 9 0.04 0.41 
5100 270 664 0.98 0.79 9 0.05 0.41 
5100 250 610 0.98 0.73 12 0.05 0.55 
5100 210 690 0.98 0.82 5 0.03 0.23 
5100 190 657 0.98 0.79 5 0.03 0.23 
5100 150 676 0.97 0.81 4 0.02 0.18 
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4900 190 683 0.98 0.82 7 0.04 0.32 
4900 150 663 0.98 0.79 8 0.04 0.36 
4900 110 663 0.98 0.79 8 0.04 0.36 
4900 70 636 0.98 0.76 9 0.04 0.41 
4900 30 720 0.98 0.86 4 0.03 0.18 
 
 
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N 
Correct 
Precision Recall N Correct Precision Recall 
5500 468 0.98 0.56 14 0.04 0.64 
5300 575 0.98 0.57 12 0.03 0.55 
5100 481 0.98 0.58 12 0.03 0.55 
4900 497 0.98 0.59 12 0.03 0.55 
4700 468 0.98 0.56 14 0.04 0.64 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
5500 19 468 0.98 0.60 14 0.04 0.64 
5500 17 722 0.98 0.86 6 0.05 0.27 
5500 15 755 0.98 0.90 4 0.05 0.18 
5500 11 725 0.97 0.87 3 0.03 0.14 
5300 19 691 0.98 0.83 8 0.05 0.36 
5300 15 674 0.98 0.81 9 0.05 0.41 
5300 11 658 0.98 0.79 8 0.04 0.36 
5100 15 670 0.98 0.81 6 0.27 0.27 
5100 11 679 0.98 0.81 9 0.05 0.41 
4900 19 706 0.98 0.84 5 0.04 0.23 
4900 15 710 0.98 0.85 6 0.05 0.27 
4900 11 679 0.98 0.81 6 0.04 0.27 
 
Sleep 
 
1. Cost-Sensitive Classification with Cost-Validation 
Yes = 34, No = 65 
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J48 
  
No 
  
Yes 
  
Cost MinNumObj N Correct Precision Recall N Correct Precision Recall 
3 20 16 0.67 0.25 26 0.35 0.77 
3 15 23 0.66 0.35 22 0.34 0.65 
3 10 23 0.70 0.35 24 0.36 0.71 
3 5 18 0.64 0.28 24 0.34 0.71 
2 20 25 0.74 0.39 25 0.39 0.75 
2 15 26 0.67 0.40 21 0.35 0.62 
2 10 43 0.71 0.66 16 0.47 0.44 
2 5 39 0.69 0.60 15 0.37 0.44 
1 20 58 0.64 0.89 2 0.22 0.06 
1 15 55 0.64 0.85 3 0.23 0.09 
1 10 57 0.66 0.88 5 0.39 0.15 
1 5 58 0.68 0.89 7 0.50 0.21 
Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
3 32 0.74 0.49 23 0.41 0.68 
2 39 0.71 0.60 18 0.41 0.53 
1 52 0.68 0.80 10 0.44 0.29 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N 
Correct 
Precision Recall 
3 20 39 0.63 0.60 11 0.30 0.32 
3 18 38 0.64 0.59 13 0.33 0.38 
3 16 35 0.65 0.54 15 0.33 0.44 
3 14 37 0.69 0.57 17 0.38 0.50 
2 20 40 0.67 0.62 14 0.36 0.41 
2 18 39 0.66 0.60 14 0.35 0.41 
2 16 39 0.65 0.60 13 0.33 0.38 
2 14 41 0.66 0.63 13 0.35 0.38 
1 20 44 0.66 0.68 11 0.34 0.32 
1 18 47 0.67 0.72 11 0.38 0.32 
1 16 47 0.68 0.72 12 0.40 0.35 
1 14 46 0.67 0.71 11 0.37 0.32 
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2. SMOTE with Percentage Split 
Training set - Yes = 20, No = 36 
Validation set - Yes = 14, No = 29 
J48 
  
No 
  
Yes 
  
SMOTE 
(%) 
MinNum 
Obj 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
150 15 5 0.56 0.17 10 0.29 0.71 
150 10 16 0.73 0.55 8 0.38 0.57 
150 5 8 0.62 0.28 9 0.30 0.64 
150 2 8 0.62 0.28 9 0.30 0.64 
100 15 10 0.56 0.35 6 0.24 0.43 
100 10 10 0.71 0.35 10 0.35 0.71 
100 5 10 0.71 0.35 10 0.35 0.71 
100 2 15 0.71 0.52 8 0.36 0.57 
50 15 6 0.50 0.21 8 0.26 0.57 
50 10 14 0.74 0.48 9 0.38 0.64 
50 5 21 0.70 0.72 5 0.39 0.36 
50 2 21 0.70 0.72 5 0.39 0.36 
 
Logistic Regression 
 
No 
  
Yes 
  
SMOTE 
(%) 
N 
Correct 
Precision Recall N 
Correct 
Precision Recall 
150 18 0.72 0.62 7 0.39 0.50 
100 19 0.73 0.66 7 0.41 0.50 
50 20 0.74 0.69 7 0.44 0.50 
 
Multilayer Perceptron 
  
No 
  
Yes 
  
SMOTE 
(%) 
Hidden 
Layers 
N Correct Precision Recall N 
Correct 
Precision Recall 
150 22 19 0.79 0.66 9 0.47 0.64 
150 20 19 0.76 0.66 8 0.44 0.57 
150 18 19 0.79 0.66 9 0.47 0.64 
150 16 17 0.81 0.59 10 0.46 0.71 
150 14 18 0.86 0.62 11 0.50 0.77 
100 22 17 0.74 0.59 8 0.40 0.57 
100 20 20 0.80 0.69 9 0.50 0.64 
100 18 20 0.77 0.69 8 0.47 0.57 
100 16 18 0.75 0.62 8 0.42 0.57 
100 14 19 0.83 0.66 10 0.50 0.71 
50 22 19 0.79 0.66 9 0.47 0.64 
50 20 18 0.78 0.62 9 0.45 0.64 
50 18 17 0.71 0.59 7 0.37 0.50 
50 16 18 0.72 0.62 7 0.39 0.50 
50 14 17 0.77 0.59 9 0.43 0.64 
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TEAMED Application 
Physiological 
1. Cost-Sensitive Classification with Cross-Validation 
Yes = 11, No = 586 
J48 
  
No 
  
Yes 
  
Cost MinNumObj N Correct Precision Recall N Correct Precision Recall 
60 90 388 0.98 0.66 2 0.01 0.18 
60 80 385 0.98 0.66 3 0.02 0.27 
60 70 435 0.98 0.74 1 0.01 0.09 
60 60 443 0.98 0.76 0 0.00 0.00 
60 50 432 0.98 0.74 0 0.00 0.00 
50 70 442 0.98 0.75 0 0.00 0.00 
50 60 451 0.98 0.77 0 0.00 0.00 
50 50 414 0.98 0.71 3 0.02 0.27 
50 40 462 0.98 0.73 2 0.01 0.18 
40 70 454 0.98 0.78 0 0.00 0.00 
40 60 441 0.98 0.75 0 0.00 0.00 
40 50 423 0.98 0.72 1 0.01 0.09 
40 40 441 0.98 0.75 2 0.01 0.18 
40 30 469 0.98 0.80 2 0.02 0.18 
40 20 482 0.98 0.82 0 0.00 0.00 
 
Logistic Regression 
 
No 
  
Yes 
  
Cost N Correct Precision Recall N Correct Precision Recall 
70 377 0.98 0.64 4 0.02 0.36 
60 406 0.98 0.69 3 0.02 0.27 
50 426 0.98 0.73 2 0.01 0.18 
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Multilayer Perceptron 
  
No 
  
Yes 
  
Cost Hidden 
Layers 
N Correct Precision Recall N Correct Precision Recall 
70 18 530 0.98 0.90 1 0.02 0.09 
70 16 479 0.98 0.82 3 0.03 0.27 
70 14 439 0.98 0.75 3 0.02 0.27 
60 16 542 0.98 0.93 1 0.02 0.09 
60 14 489 0.98 0.83 3 0.03 0.27 
50 22 546 0.98 0.93 0 0.00 0.00 
50 20 516 0.98 0.88 1 0.01 0.09 
50 18 535 0.98 0.91 0 0.00 0.00 
50 16 556 0.98 0.95 0 0.00 0.00 
50 14 554 0.98 0.95 0 0.00 0.00 
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Appendix 2.7 Major Research Project Proposal 
Technology Evaluating and Measuring Emotional Dysregulation (TEAMED) 
 
Background: 
Challenging behaviour is a significant issue for people with an acquired brain injury (ABI), 
and can impact everyday functioning. Research has explored medication, psychological and 
environmental interventions. The development of portable wearable devices that measure 
real-time physiological states opens avenues for assessing the predictability of challenging 
behaviour for future prevention via biofeedback intervention.  
 
Aims: 
To explore whether a physical monitoring device (electronic watch) can accurately predict 
challenging behaviour in individuals with an ABI. 
 
Method: 
A prospective case series design will be used. Participants will be recruited from Graham 
Anderson House. Participants will have sustained a severe brain injury, be ≥16 years old, 
and present with challenging behaviour. Patients with severe cognitive impairment will be 
excluded. Written consent will be sought from participants. Participants will wear an 
electronic watch that monitors heart rate, galvanic skin response, skin temperature and 
movement for up to 12 weeks. NHS Ethical approval for the project will be sought from the 
West of Scotland Research Ethics Committee. Approval via the MHRA and NHS R&D is 
not required.  
 
 
Applications: 
Identification of a tool that can predict challenging behaviour would be valuable for patients 
and staff by opening avenues for its prevention via proactive strategies.  
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Introduction 
Challenging behaviour following acquired brain injury (ABI) is a significant issue for both 
patients and care providers (Tateno et al, 2003). These behaviours, if poorly controlled, can 
lead to difficulties with educational, vocational, and social pursuits, and family re-integration 
(Morton and Wehman, 1995; Ylvisaker et al, 2005). A study of 507 patients with severe ABI 
reported 54% to display challenging behaviour; inappropriate social behaviour was most 
commonly reported (33%; Sabaz et al, 2014). Difficulty identifying emotions, empathy, 
emotion regulation, social cognition and alexithymia are also found to be more prevalent 
following an ABI than the general population (McDonald, 2013; Wood and Williams, 2007).  
 
Warden et al (2006) reviewed 33 pharmacological studies, and found supportive evidence 
for the use of medication for the treatment of aggression in people with a ABI; these included 
betablockers, methylphenidate, serotonin reuptake inhibitors, lithium, and tricyclic 
antidepressants. They also summarised evidence supporting cranial electrical stimulation 
and homeopathy, despite only one study identified for either intervention. They did not 
support the use of carbamazepine, pyritinol, valproate, estrogen and amantadine. Ylvisaker 
et al (2007) systematically reviewed 65 non-pharmacological studies (n = 172) for children 
or adults with behaviour disorders following an ABI; all studies reported an improvement in 
behavioural functioning. Interventions included contingency management, applied 
behavioural analysis and positive behavioural support. However, conclusions are restricted 
by methodological limitations: only two of the 65 studies were randomised controlled trials, 
with small sample sizes that did not record challenging behaviour frequency; the majority 
were uncontrolled single-cases or a series of cases. Other limitations include the lack of 
standardised intervention procedures, failure to report previously attempted failed 
interventions, and failure to record long-term outcomes (Ylvisaker et al, 2007). 
Psychological and behavioural interventions have also been recommended to treat the 
clinical correlates of aggressive behaviour following an ABI e.g. mood disorders, substance 
abuse, poor social support (Tateno, 2003). However research is limited, highlighting the 
need to explore further intervention options. 
 
The evidence for the role of biofeedback, using physiological data, to improve emotion 
regulation is limited in the brain injury population; although there is some evidence for its 
role in improving cognitive functioning (Thatcher, 2000). Interventions have mainly 
provided neurofeedback to participants via the operant conditioning of preferable brain wave 
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patterns recorded via electroencephalography (Thatcher, 2000). In other populations 
supportive evidence has explored the use of biofeedback from skin temperature, muscle 
tension and brain waves for the treatment of chronic pain, urinary incontinence, high blood 
pressure and headaches (e.g. Cvjetičanin and Bašic, 2016; Dannecker et al, 2005). There is 
some evidence supporting the relationship between physical recordings and antisocial and 
violent behaviour in non-brain injured individuals (e.g. heart rate; Raine, 2002), but both 
correlation and intervention research is limited in the brain injury population. With the 
emergence of portable physiological monitoring systems this can broaden research 
opportunities, which have previously relied on patients being wired into large computer 
equipment, by allowing patients to wear the devices throughout the day.  
 
The Graham Anderson House is a brain injury rehabilitation unit provided by the Brain 
Injury Rehabilitation Trust (BIRT) for people with complex needs that require residential 
care and support. Many patients resident at the Graham Anderson House require staff 
intervention to help manage challenging behaviours (i.e. harm to the patient or staff) as the 
patient is unable to identify and/or self-manage difficult emotions appropriately. With the 
developments in technology leading to the creation of Smart Watches, individuals can now 
accurately record and review their own physiological data (e.g. heart rate variability, sleep, 
movement). Developments in machine learning have also opened avenues for identifying 
useful patterns in data. It would be clinically relevant to be able to use machine learning 
techniques to find patterns in patients physiological data that would help predict future 
challenging events; this would provide opportunities for intervention that could then prevent 
future harmful behaviours. Therefore the current study aims to complete an exploratory 
investigation into whether a machine-learning algorithm can be used to predict challenging 
behaviour using physiological data.  
 
Aims  
To investigate whether a machine learning algorithm can be used to predict challenging 
behaviour episodes, using physiological data. 
 
Research Questions 
Can a machine learning algorithm be used to predict challenging behaviour using 
physiological data? 
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What levels of precision (positive predictive value) and recall (sensitivity) are obtained when 
machine learning algorithms are applied to physiological data? 
 
Hypothesis 
A machine learning algorithm can be used to predict challenging behaviour using 
physiological data. 
 
Plan of Investigation 
Participants 
Patients with a brain injury, who are resident in a BIRT unit and present with challenging 
behaviour during the recruitment period. 
 
Inclusion Criteria 
- Patients who have sustained a severe injury to the brain, as determined by length of 
unconsciousness (greater than 6 hours) and a Glasgow Coma Scale of 3 to 8. 
- Participants who have the capacity to consent to participation in research defined as 
understanding: 
o the type of physiological data the watch is collecting (sweat, heart rate, 
movement, sleep, temperature) 
o what the data is being used for (i.e. whether the data can predict episodes of 
physical or verbal violence) 
o that their participation involves wearing the watch for 8 weeks 
o that they can withdraw from the study at any time 
o that their data will be anonymised  
- Patients who are resident in the Graham Anderson House BIRT Unit throughout the 
duration of the study. 
- Patients ≥16 years old 
- Patients presenting with challenging behaviour, during the recruitment period 
- Patients will not be excluded on the basis of comorbid psychiatric disorders or histories 
of drug/alcohol misuse, in order to provide conclusions representative of the clinical 
population 
 
Exclusion Criteria 
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- Patients without the capacity to consent to participation in research. 
 
Recruitment Procedures 
Patients will be recruited from the Graham Anderson House BIRT unit and approached by 
their clinical care team regarding participation in the study. Informed consent will be sought 
from the individual, after providing information about the study, by a member of the research 
team. They will be given at least 24 hours to decide whether to participate in the study. 
Patients that cannot provide consent will not be eligible to participate in the study. 
 
Measures 
The primary outcome of accuracy of prediction of challenging behaviour episodes will be 
determined through the predictive ability of the machine learning algorithm. This involves 
collecting physiological data using an electronic watch, and collecting challenging 
behaviour events using a clinical tool. Challenging behaviour episodes will be recorded via 
an adapted OAS-MNR (Alderman et al, 1997). The OAS-MNR is routinely used at the 
Graham Anderson House to record challenging behaviour and therefore this information will 
be collected from the patients’ medical notes and anonymised for analysis procedures. As 
the staff at Graham Anderson House reporting this information are not involved in the study 
and have no conflict of interest, and the monitoring devices are commercially available and 
in similar appearance to a variety of Smart Watches, they are considered blind and 
independent raters of challenging behaviour. All types of behaviour recorded on the OAS-
MNR will be considered an event. 
 
Participants will wear a portable physiological monitoring device, Microsoft Band 2, which 
will record heart rate variability, movement, galvanic skin response, skin temperature and 
sleep. Data will be collected over for up to 12 weeks. A WIFI connected phone will store 
the physiological data, which will then be sent to a secure server managed by the University 
of Stirling, before being extracted for storage on a password protected Brain Injury 
Rehabilitation Trust computer. No personal identifiable information will be recorded on the 
watch and therefore all physiological data will be anonymised and linked to the patient via 
a unique ID kept separately on a password protected NHS computer known only to the 
researcher cannot be linked to the patient.  
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Demographic and clinical characteristics (e.g. age, gender, brain injury severity) will be 
gathered from each participants’ medical records. 
 
Design 
Due to the nature of the study, a case series design will be used. 
 
Research Procedure 
Following enrolment in the study, participants will wear the watch for up to 12 weeks. 
During this time, staff will complete the adapted OAS-MNR, as per standard clinical care, 
when a challenging behaviour event occurs; this will describe the situation in which the event 
occurred, participant and staff responses, and any resulting behaviours, including the 
occurrence of challenging behaviour. Following an initial period of data collection, this data 
will be used in the creation and validation phase of the machine learning algorithm. The 
second period of data collection will be used to test the machine learning algorithm (see Data 
Analysis Section). Throughout the study, staff will respond to challenging behaviour events 
as per standard care. During participation, data will be stored on a secure data server (see 
Data Handling below). 
 
Data Handling 
A WIFI connected phone will store the physiological data measured by the Watch. This data 
will then be sent to a University of Stirling managed secure server, before being extracted 
for storage on a password protected Brain Injury Rehabilitation Trust computer. No personal 
identifiable information will be recorded on the watch and therefore all physiological data 
will be anonymised confidential, with the identity known only to the researcher. The data 
will only be linked via a unique ID held separately from both the consent forms and the study 
data. Consent forms will be stored at Graham Anderson House in the participants’ medical 
files, accessible by the clinical team; medical files will not be accessible to the research team 
more than 3 months after the study has ended.  
 
Data Analysis 
The machine-learning package WEKA (Waikato Environment for Knowledge Analysis) 
will be used to analyse the physiological and behavioural data. A proportion of the data 
sampled will be used to create and validate a machine-learning algorithm. As this is an 
exploratory study, if possible, multiple models may be created in order to determine the most 
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appropriate algorithm(s); this may mean the development of a generic model, a specific 
model adapted for each patient, or separate models of verbal or physical aggression events. 
As the data involves time series data, temporal dependencies in the data will be accounted 
for via machine learning methods (e.g. sliding window approach). Events will be determined 
via staff completion of the adapted OAS-MNR within an hour window, non-events will be 
determined via a one hour window of non-completion of the adapted OAS-MNR. This 
process will also involve exploring the most appropriate level of sensitivity (aka. recall) and 
positive predictive value (aka. precision); this will include exploring the clinical 
applicability. The remaining data collected will be used to test the final machine learning 
algorithm(s). Dr Kevin Swingler (Lecturer in Computing Science, University of Stirling) 
and Professor Ken Turner (Emeritus Professor, University of Stirling) will provide guidance 
regarding data analysis, where required. 
 
Justification of sample size 
The number of residents at the BIRT unit restricts the number of patients potentially eligible 
for inclusion. During the recruitment period, it was estimated that at least 8 patients were 
considered to be eligible. Considering this, alongside the novel nature and case series design, 
the timescale of the project deadline, and the number of watches available, four participants 
was suggested to be appropriate for inclusion for thesis submission. This was considered to 
be sufficient to provide preliminary findings as to the predictability of machine learning 
algorithm(s) in predicting challenging events occurring in people with ABI. Up to a further 
4 participants may then be recruited, with the total 8 participants included for submission to 
a peer reviewed journal. An 12-week schedule was chosen to balance length of time 
participants needed to wear the watch, to account for any periods of missing data, and 
ensuring enough time had passed for enough occurrences of challenging behaviour episodes; 
the average occurrence of challenging behaviour episodes at BIRT, per patient, is 
approximately 25 events per week. 
 
Health and Safety Issues 
See Health and Safety Form (Appendix 2) 
Researcher Safety Issues 
Due to the patient population investigated, safety issues relating to challenging behaviour 
may be present. The researcher will have received adequate training and be aware of local 
policy procedures should a safety issue arise. Due to the specialist nature of the service, staff 
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will be adequately trained in supporting this population during episodes of challenging 
behaviour for the duration of the study.  
 
Participant Safety Issues 
Due to the patient population investigated, participants may find it difficult to understand 
the purpose of the study and that a watch is being used to predict future challenging 
behaviour events. This may lead to reluctance to engage with the study. As the participants 
are resident at the rehabilitation unit, if any participant becomes distressed at any time during 
the study they will have access to their clinical care team for support. Participants have the 
right to withdraw from the study at any time. There is also a noted safety issue regarding the 
possibility of a skin reaction to the watch itself. As the participants are resident at the 
rehabilitation unit, their mental and physical health is regularly assessed. If any participant 
indicates or appears to show signs of a skin reaction, the watch will be removed and 
appropriate treatment will be provided. The participant will no longer wear the watch and 
will be withdrawn from the study. 
 
Ethical Issues 
NHS Ethical approval for the project will be sought from an NHS Research Ethics 
Committee. Approval via the Medications and products Healthcare Regulatory Authority 
was not required, as the study involves no randomisation, change to standard treatment or 
aims to claim generalisation of findings. NHS Research and Development approval will not 
be sought as the research will be conducted at a non-NHS site. 
 
Financial Issues 
See Costs and Equipment Form (Appendix 3) 
Financial costs include printing costs for consent forms and participant information sheets. 
Portable devices to record physiological measures will be provided by the Graham Anderson 
House. 
 
Dissemination Plan 
The research will be submitted as part of the thesis component of the Doctorate in Clinical 
Psychology academic programme. This will be accessible via the e-library at the University 
of Glasgow. Details of the results will be provided to participants via their care team. The 
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research team also plan to submit the research as a manuscript for publication in a peer 
reviewed journal. 
 
Proposed Timetable 
September 2017   Systematic Review Outline 
Wednesday 17th January  Ethics Paperwork 
Thursday 18th January 2018  Draft Proposal 
Thursday 1st February 2018 Proposal  
March 2018-May 2018  Data Collection 
April-June 2018   Data Analysis 
June 2018    Draft Thesis 
27 July 2018    Final Thesis 
September 2018   VIVAS 
 
Practical Applications 
The identification of physiological measures that predict behaviours that challenge services 
would provide important warning signs to indicate intervention by staff to prevent the 
behaviour from occurring. This would have significant implications as to the frequency and 
severity of behaviours that challenge services. 
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